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SURGICAL MANAGEMENT AND OUTCOME FOLLOWING ADRENALECTOMY: A 
RETROSPECTIVE CASE STUDY IN 16 DOGS (2008-2018). 
 
 
Primary neoplasms of the adrenal gland might represent more than 1-2% of all canine tumours 
and can originate various worrisome clinical presentations; hence why adrenalectomy is 
generally the treatment of choice. Identification of prognostic factors with occasional 
uncertainty or contradictions among different authors renders further investigations welcomed. 
A retrospective study was conducted in 16 dogs undergoing adrenalectomy with the aim to 
describe the clinical features, surgical management and outcome. 
Review of clinical records and interviews with owners and veterinarians involved were 
performed to register clinical variables, such as, signalment, relevant history, clinical signs, 
laboratory, imaging and surgical findings, histopathology results, and outcome. The median 
survival time was calculated through Kaplan-Meier estimate. 
Intra- (92%) and postoperative (67%) complications, and perioperative mortality (31%) rates 
were comparable to recent studies; as was the median survival time (419 days), with 64% of 
long-term survivors living for more than 1 year, up to 3 years, approximately. 
This case series emphasizes that if dogs survive the immediate perioperative period, long-term 
outcome is generally good with possibility of prolonged survival times, as local or distant 
tumour recurrence appears to be low. This study also promotes awareness of adrenal 
incidentalomas (25%) and emergency clinical presentations (19%). Outcome predictors such 
as age of patients with phaeochromocytomas, size of tumour, surgeon’s experience in dealing 
with caval invasion, presence of metastasis at surgery, acute adrenal haemorrhage, major 
intraoperative haemorrhage, and postoperative disseminated intravascular coagulopathy must 
be considered in the approach to these cases.  
 
 













MANEIO CIRÚRGICO E RESULTADO APÓS ADRENALECTOMIA: UM ESTUDO 
RETROSPETIVO DE CASOS EM 16 CÃES (2008-2018). 
 
 
Neoplasias primárias das glândulas adrenais poderão representar mais do que 1-2% de todos os 
tumores caninos e podem originar vários quadros clínicos preocupantes; e por isso é que a 
adrenalectomia é geralmente o tratamento de escolha. A identificação de fatores de prognóstico 
com incerteza ou contradições ocasionais entre diversos autores ditam que investigações 
adicionais sejam bem-vindas. 
Um estudo retrospetivo foi conduzido em 16 cães submetidos a adrenalectomia, para descrever 
o quadro clínico, maneio e resultado cirúrgico. 
Foi feita a revisão de historiais clínicos e entrevistas a donos e veterinários envolvidos de forma 
a registar variáveis clínicas como identificação do animal, historial relevante, sinais clínicos, 
achados laboratoriais, imagiológicos e cirúrgicos, resultados de histopatologia, e resultado. A 
mediana dos tempos de sobrevivência foi calculada através da estimativa de Kaplan-Meier. 
As taxas de complicações intra- (92%) e pós-cirúrgicas (67%), e de mortalidade (31%) foram 
comparáveis a estudos recentes; assim como o tempo mediano de sobrevivência (419 dias), 
com 64% dos sobreviventes a longo prazo a viveram por mais de 1 ano, até 3 anos, 
aproximadamente. 
Esta série de casos enfatiza que se os cães sobreviverem o período peri-cirúrgico imediato, o 
resultado a longo prazo é geralmente bom com possibilidade de tempos de sobrevivência 
prolongados, uma vez também que a taxa de recorrência local ou distante aparenta ser baixa. 
Este estudo promove também a consciencialização de incidentalomas das adrenais (25%) e de 
quadros clínicos de emergência (19%). Fatores de prognóstico tais como idade dos pacientes 
com feocromocitomas, tamanho do tumor, experiência do cirurgião em lidar com invasão da 
veia cava, presença de metástases na altura da cirurgia, hemorragia aguda adrenal, hemorragia 
intra-cirúrgica de maior importância, e coagulopatia intravascular disseminada pós-cirúrgica, 
devem ser considerados na abordagem a estes casos.   
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As part of the Integrated Master’s Degree in Veterinary Medicine from the Faculty of 
Veterinary Medicine of the University of Lisbon, I fulfilled a 6-month training period between 
the 4th of September 2017 and the 16th of March 2018, in a total of roughly 1100 hours, at 
Kingston Veterinary Group, Hull, United Kingdom. Throughout that period, I assisted and 
participated in numerous procedures carried out in different areas of small animal veterinary 
medicine. In the Surgery department, led by Dr. David Robinson, who was also my mentor and 
supervisor, I cooperated by helping in several orthopaedic procedures (e.g. closing-wedge 
osteotomy, fabello-tibial suture, tibial tuberosity transposition, fracture repairs, pancarpal 
arthrodesis, placement of transcondylar screw for correction of incomplete ossification of 
humeral condyle, stabilization of coxofemoral luxation using the toggle pin method), soft tissue 
surgeries (e.g., exploratory laparotomies, laparoscopies, cystotomies, splenectomies, 
gastrotomy, enterotomy, perineal hernia repair, anal sacculectomy, incisional/excisional 
biopsies, brachycephalic obstruction airway syndrome surgery, patent ductus arteriosus 
ligation, bilateral thyroidectomy, cholecystectomy, adrenalectomy, grid keratectomy, 
temporary eyelid tacking) and postoperative care of the patients. Furthermore, I was also given 
the opportunity to develop my surgical skills by performing several surgical procedures under 
the supervision of senior surgeons, such as dog, cat and rabbit castrations, dog and cat 
ovariohysterectomies, umbilical hernia repair, dewclaw removal, aural haematoma repair, 
superficial nodule/mass excision, mastectomy, pyometra, cystotomy, and dentistry procedures 
such as teeth extraction, scaling and polishing. The same applies in terms of Anaesthesia, 
considering I was able to practice procedures such as induction, intubation and general 
anaesthetic monitoring. In the Internal Medicine department, I worked on my clinical case 
solving skills and participated in the care and treatment of the inpatients, practicing procedures 
such as drugs administration, blood sampling, blood typing, collection and transfusion, venous 
and urinary catheterization, cystocentesis and running several diagnostic tests. In addition, I 
accompanied clinicians during consultations and was also able to take the lead and develop my 
consulting skills. Finally, with regards to the Diagnostic Imaging department, I assisted the 
surgeons during endoscopy (rhinoscopy, bronchoscopy, gastroscopy) and ultrasound, magnetic 
resonance imaging and computed tomography scans. Moreover, I was able to practice patient 
positioning for radiographic examination. During and after these procedures, I was taught by 
senior vets how to interpret the results and to take conclusions towards diagnostic and treatment 





Primary neoplasms of the adrenal gland were reported to account for 1 to 2% of all canine 
tumours, though nowadays it is arguable that this fraction might have been undervalued (Lunn 
& Page, 2013; Myers, 1997). In the past years, both medical and veterinarian practitioners have 
witnessed an escalation in discovery of incidental adrenal lesions (incidentalomas), along with 
an uncertainty regarding the right manner to address them. The widespread availability of 
advance diagnostic imaging methods (especially ultrasonography, but also computed 
tomography and possibly, on a minor role, magnetic resonance imaging) hold the responsibility 
in this matter (Baum, Boston, & Case, 2016; Cook, Spaulding, & Edwards, 2014; Myers, 1997). 
The most common types of tumours are, in descending order, cortical adenomas, carcinomas, 
medullary phaeochromocytomas, and secondary neoplasic lesions (Labelle & De Cock, 2005; 
Lunn & Page, 2013; Reusch, 2015). Any of these can be associated with a rather vast variety 
of worrisome clinical scenarios such as endocrine/neuroendocrine derangements (Barthez, 
Marks, Woo, Feldman, & Matteucci, 1997; Gilson, Withrow, Wheeler, & Twedt, 1994; Reusch 
& Feldman, 1991; van Sluijs, Sjollema, Voorhout, van den Ingh, & Rijnberk, 1995), local 
compression or invasion of near-by structures like the ipsilateral kidney and major vessels (e.g., 
CVC), metastatic disease, and a surgical emergency caused by acute rupture and consequent 
haemoabdomen or -retroperitoneum (Barrera, Bernard, Ehrhart, Withrow, & Monnet, 2013; 
Kyles et al., 2003; Lang et al., 2011; Vandenbergh, Voorhout, van Sluijs, Rijnberk, & van den 
Ingh, 1992; Whittemore, Preston, Kyles, Hardie, & Feldman, 2001). 
Generally, adrenalectomy is the treatment of choice, even though it is a technical demanding 
procedure, associated to considerably high perioperative complications and mortality rates. Yet, 
more recent studies reported lower mortality, varying from 12 to 26% (Barrera et al., 2013; 
Kyles et al., 2003; Lang et al., 2011; Massari, Nicoli, Romanelli, Buracco, & Zini, 2011; 
Schwartz et al., 2008). Furthermore, good long-term outcome with prolonged survival times is 
possible, provided that dogs survive the perioperative period (Anderson et al., 2001; Barrera et 
al., 2013; Barthez et al., 1997; Gilson, Withrow, & Orton, 1994; Kyles et al., 2003; Lang et al., 
2011; Massari et al., 2011; Schwartz et al., 2008; van Sluijs et al., 1995). 
Several authors have appointed a number of variables with or without prognostic significance 
for dogs with adrenal tumours undergoing adrenalectomy (Anderson et al., 2001; Barrera et al., 
2013; Herrera et al., 2008; Kyles et al., 2003; Lang et al., 2011; Massari et al., 2011; Schwartz 
et al., 2008). Yet, because of the existence of a certain degree of uncertainty or contradictions 
between studies regarding some of the identified factors, further investigations on the subject 
are welcomed.  
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1. NEOPLASMS OF THE ADRENAL GLANDS AND DIAGNOSTIC APPROACH 
1.1 Types of neoplasms 
1.1.1 Neoplasms of the adrenal cortex 
Adrenocortical tumours (ATs), namely, adenomas and carcinomas, are the most frequently seen 
adrenal gland neoplasms (Barrera et al., 2013; Kyles et al., 2003; Labelle & De Cock, 2005; 
Lang et al., 2011; Massari et al., 2011; Oblak, Bacon, & Covey, 2016; Schwartz et al., 2008). 
Adenomas are classically single, well-demarcated nodules, partially or completely 
encapsulated by fibrous connective tissue and a compressed border of cortical parenchyma. 
While small adenomas tend to maintain a yellow colour similar to the normal cortex, larger 
ones vary from yellow to red, deform the gland’s external surface, and may extend into the 
medulla. Though similar, discrete adenomas differ from nodular hyperplasia predominantly due 
to the latter inexistence of encapsulation signs along with the typical presence of multiple 
nodules on both adrenal glands (Rosol & Gröne, 2016). Histologically, adenoma tumour cells 
are well-differentiated with resemblances of normal zonae fasciculata or reticularis cells. 
Organised in broad trabeculae or nests divided by small vascular spaces, the cells present 
abundant lightly eosinophilic cytoplasm, frequently vacuolated and filled with several lipid 
droplets. Foci of mineralisation, haematopoiesis, and adipose tissue accumulations can be 
demonstrated, as well as, fibrin thrombi allocated in large dilated blood-filled sinusoids 
(telangiectasis) (Labelle et al., 2004; Rosol & Gröne, 2016). 
Cortical carcinomas arise less commonly in comparison to adenomas (Labelle & De Cock, 
2005; Rosol & Gröne, 2016). Carcinomas tend to be larger and are more likely to occur 
bilaterally. They are constituted by variegated, yellow to red, friable, tissue that incorporates 
the disturbed adrenal. This malignant AT is commonly locally fixed due to extensive invasion 
of surrounding structures, namely, the CVC and aorta, resulting in potential large tumour 
thrombi (Rosol & Gröne, 2016). Histologically, the normal architecture of the gland is often 
completely destructed by the malignant neoplasm. Tumoural cells are highly pleomorphic – not 
only typically large and polyhedral with prominent nuclei and densely eosinophilic or 
vacuolated cytoplasm, but also smaller cells may be present –, form clusters, and are subdivided 
by fibrovascular stroma. Areas of haemorrhage may be demonstrated as result of rupture of 
thin-walled sinusoids. The growth pattern varies between tumours and within the same one. 
Moreover, this feature may be used to distinguish between carcinomas in regard to their type 
of invasion. Specifically, the existence of a trabecular growth pattern in a minimum of 1/3 of 
the tumour was significantly more frequent in carcinomas with metastases compared with 
carcinomas with vascular invasion alone (Labelle et al., 2004). In their study, Labelle et al. 
(2004) also found that ~50% (14/26) of dogs with carcinomas had metastases, mainly spreading 
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to the liver and lungs, but also, kidneys, ovary and mesenteric lymph nodes. Other reported 
locations include thyroid vessels, serosal surfaces of liver and pylorus, and small intestines 
(Anderson et al., 2001; Barrera et al., 2013). Furthermore, Labelle et al. (2004) noted that 
metastases may be seen with or without vascular invasion, and vice versa. Vascular invasion, 
specifically caval thrombi, may be formed via direct penetrating entry into the CVC lumen 
through the adrenal capsule and vascular wall; or via the common trunk (former 
phrenicoabdominal vein) creating a stalked thrombus (Kyles et al., 2003). In addition to local 
and distant spread, the clinical presentation may still be complicated by compression of other 
organs by a large tumour (i.e., mass-effect), or by an haemoabdomen due to non-traumatic 
rupture of the neoplasm (Rosol & Gröne, 2016; Whittemore et al., 2001). 
Whereas differentiation between the adenomas and carcinomas might be challenging, 
combination of immunohistochemical assessment of the Ki-67 proliferation index with an 
established group of histologic criteria may simplify the distinction. Features significantly 
associated with carcinomas included having > 2 cm in diameter, peripheral fibrosis, capsular 
invasion, trabecular growth pattern, haemorrhage, necrosis, and significantly higher Ki-67 
proliferation index; as opposed to extramedullary haematopoiesis, fibrin thrombi, cytoplasmic 
vacuolation, which were features significantly associated to adenomas (Labelle et al., 2004). 
Occasionally, cortical adenomas and carcinomas are endocrinologically active and produce 
excessive quantities of hormones (glucocorticoids, mineralocorticoids, sex-hormones, steroid 
precursors) in autonomously and randomly manner. Cortisol-producing tumours are by far the 
most common in dogs and represent approximately 15% of canine hyperadrenocorticism 
(Cushing’s syndrome). As a consequence of the negative feedback inhibition of pituitary ACTH 
(adrenocorticotropic hormone) secretion exerted by the hypercortisolaemia (or other 
intermediates), the contralateral cortex atrophies leaving only the adrenal capsule and the zona 
glomerulosa. In the remaining zonae (fasciculata and reticularis) only a few secretory cells may 
be identified. The same atrophy may be demonstrated in the remnants of compressed cortex 
delimitating producing adenomas (Behrend, 2015; Reusch, 2015; Rosol & Gröne, 2016). In 
contrast, aldosterone (Johnson et al., 2006; Rijnberk et al., 2001) and sex-hormone (e.g., 17-
hydroxyprogesterone, progesterone, estradiol, androstenedione) (Benitah, Feldman, Kass, & 
Nelson, 2005; Norman, Thompson, & Mooney, 1999; Ristic, Ramsey, Heath, Evans, & 
Herrtage, 2002; Syme et al., 2001) secreting-lesions are found very rarely in dogs (Behrend, 
2015; Reusch, 2015). Likewise, production of other intermediates (e.g., deoxycorticosterone 
and corticosterone) is uncommonly reported, as well as, tumours that release multiple types of 
hormones and with different functions: solely deoxycorticosterone (Gójska-Zygner, 
Lechowski, & Zygner, 2012; Reine, Hohenhaus, Peterson, & Patnaik, 1999); 
 5 
deoxycorticosterone and cortisol (Davies et al., 2008); corticosterone and aldosterone (Behrend 
et al., 2005; Frankot, Behrend, Sebestyen, & Powers, 2012); corticosterone, aldosterone, and 
cortisol (Machida et al., 2008). 
Lastly, although infrequently seen, myelolipomas are another type of benign adrenocortical 
neoplasms, endocrinologically inactive, composed of nodular collections of well-differentiated 
fat and hematopoietic tissue cells with foci of bone formation. Their origin is unclear, however, 
it is theorised that they result from metaplastic transformation of cortical cells (Rosol & Gröne, 
2016; Tursi, Iussich, Prunotto, & Buracco, 2005). 
 
1.1.2 Neoplasms of the adrenal medullary secretory cells 
After adrenocortical adenomas and carcinomas, phaeochromocytomas are the most common 
canine adrenal tumours, and the most frequent neoplasms to arise from the adrenal medulla of 
animals (Barrera et al., 2013; Kyles et al., 2003; Labelle & De Cock, 2005; Lang et al., 2011; 
Massari et al., 2011; Oblak et al., 2016; Rosol & Gröne, 2016; Schwartz et al., 2008). 
Originating from the chromaffin cells of the adrenal medulla, most phaeochromocytomas are 
unilateral and < 10% are bilateral. Although seldom in veterinary medicine, other chromaffin 
cells neoplasms sited in other locations of the body may arise. These are designated as 
paragangliomas or extra-adrenal phaeochromocytomas – for example, the aortic-sympathetic 
ganglion (organ of Zuckerkandl) near the adrenal gland (Lunn & Page, 2013; Reusch, 2015; 
Rosol & Gröne, 2016). 
Histologically, the neoplastic cells may alternate from small cuboidal or polyhedral to large 
pleomorphic, with several hyperchromatic nuclei and a lightly eosinophilic and finely granular 
cytoplasm. They are typically subdivided into small lobules by fine septal tissue and capillaries 
(Rosol & Gröne, 2016). 
Benign phaeochromocytomas are generally small and remain confined to the affected adrenal 
gland, completely encapsulated by a thin compressed border of cortex (Rosol & Gröne, 2016). 
In dogs, though, more than 50% are considered malignant due to their capacity to cause 
compression on or invade local structures (vessels in particular) and/or to spread distantly 
(Reusch, 2015; Rosol & Gröne, 2016). If the 3 largest case series concerning dogs with 
phaeochromocytomas are considered (Barthez et al., 1997; Bouayad, Feeney, Caywood, & 
Hayden, 1987; Gilson, Withrow, Wheeler, et al., 1994), while local invasion occurred in 39% 
to 62% of dogs, metastases were identified in 13% to 36% of dogs. Local invasion included 
surrounding organs (e.g., kidney) and/or vessels (e.g., phrenicoabdominal venous trunk, CVC, 
renal and adrenal vessels, hepatic veins, abdominal aorta). Target-organs for metastatic spread 
were regional lymph nodes, liver, lungs, spleen, kidneys, bone (e.g., vertebra, ribs), central 
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nervous system, heart, pancreas, peritoneum, jejunum. Furthermore, local invasion, namely 
caval thrombi, has been consistently reported to occur more frequently in dogs with 
phaeochromocytomas (Barrera et al., 2013; Bouayad et al., 1987; Herrera et al., 2008; Kyles et 
al., 2003; Lang et al., 2011; Twedt & Wheeler, 1984) in comparison to those with ATs 
(Anderson et al., 2001; Barrera et al., 2013; Kyles et al., 2003; Lang et al., 2011; Scavelli, 
Peterson, & Matthiesen, 1986). 
Phaeochromocytomas may be functional and therefore result in clinical signs associated with 
an overproduction of catecholamines. Tumoural cells may secrete epinephrine, norepinephrine, 
or both, and can be distinguished by the morphology of their secretory granules (Rosol & 
Gröne, 2016). 
 
1.1.3 Neoplasms of cells of the sympathetic nervous system in the adrenal medulla 
These are tumours rarely seen in domestic animals: neuroblastomas and ganglioneuromas. 
Neuroblastomas originate from primitive neuroectodermal cells and give origin to large 
intraabdominal masses. Histologically, they may be distinguished from phaeochromocytomas 
by its small and undifferentiated cells with hyperchromatic nuclei and scarce cytoplasm. Not 
only pseudorosettes may form, but also neurofibrils or unmyelinated nerve fibbers may be seen. 
They typically occur in young animals (Rosol & Gröne, 2016). 
Ganglioneuromas are benign, well-differentiated and generally small neoplasms that can be 
found in the adrenal medulla. They are composed of multipolar ganglion cells and neurofibrils 
with a prominent fibrous connective tissue stroma. Sometimes, adjacent phaeochromocytomas 
and ganglioneuromas may be seen in the same gland due to divergent differentiation of the 
tumoural cells (Rosol & Gröne, 2016). 
 
1.1.4 Metastatic neoplasms to the adrenal medulla 
The adrenal glands are a common location for secondary neoplastic development, namely, the 
adrenal medulla which represents an early site of metastasis growth as a result of the low-
pressure venous blood supply. Due to the adrenal capsule, direct invasion from either primary 
or secondary tumoural lesions from surrounding tissues is rare. Invasion is usually bilateral and 
typically results from disseminated malignancies (Rosol & Gröne, 2016). A study showed that 
metastatic lesions represented 26.7 % of all canine adrenal neoplasms, mainly originating from 
pulmonary, mammary, prostatic, gastric and pancreatic carcinomas, and melanoma (Labelle & 
De Cock, 2005). Therefore, it represents an important differential of adrenal masses. 
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1.1.5 Bilateral tumours, Concurrent PDH (pituitary-dependent hyperadrenocorticism) 
and Concurrent endocrine neoplasias 
Diverse combinations of bilateral ATs have been reported including bilateral adenomas, 
carcinomas, or a combination of adenoma and carcinoma; combinations which might be 
causing HAC (Adissu, Hayes, Wood, & Caswell, 2010; Anderson et al., 2001; Ford, Feldman, 
& Nelson, 1993; Kyles et al., 2003; Lang et al., 2011; Nabeta et al., 2017; Oblak et al., 2016; 
Stenske, Bemis, Hill, & Krahwinkel, 2005). 
Additionally, ATs have also been reported together with phaeochromocytomas as one neoplasm 
per gland (Hylands, 2005; Oblak et al., 2016; Thuróczy et al., 1998; von Dehn, Nelson, 
Feldman, & Griffey, 1995),  or even, as both on the same gland (Lang et al., 2011; Thuróczy et 
al., 1998; van Sluijs et al., 1995). 
Furthermore, PDH or pituitary tumours may be encountered with ATs (Greco, Peterson, 
Davidson, Feldman, & Komurek, 1999; Oblak et al., 2016; Thuróczy et al., 1998) or with 
phaeochromocytomas (Bennett & Norman, 1998; Oblak et al., 2016; von Dehn et al., 1995). 
In light of these reports, it is arguable that some of these patients might suffer from a multiple 
endocrine neoplasia (MEN)-like syndrome, when two or more endocrine tumours and/or 
hyperplasias that resemble one of the MEN syndromes described in humans are found in the 
same animal (Beatrice et al., 2018). MEN syndromes are well-known in human medicine and 
are divided into four major types according to the mutated gene involved and associated group 
of endocrine glands affected – types 1 to 4 (MEN1 to MEN4 syndromes) (Thakker, 1998, 2014; 
Thakker et al., 2012): 
- MEN1 syndrome combines parathyroid adenoma (90% of cases), entero-pancreatic 
tumours (30-70% of cases), pituitary adenomas (30-40% of cases), and other associated 
neoplasms; 
- MEN2 (formerly MEN2A) syndrome includes medullary thyroid cancer (90% of cases), 
phaeochromocytoma (50% of cases), and parathyroid adenoma (20-30% of cases); 
medullary thyroid cancer may occur alone as a MEN2 syndrome variant; 
- MEN3 (formerly MEN2B) syndrome groups medullary thyroid carcinoma (>90%), 
phaeochromocytoma (40-50%), and other associated abnormalities; 
- MEN4 (or MENX) syndrome is the newest reported variant and combines MEN1 
syndrome target structures (parathyroid adenoma, pituitary adenoma, pancreatic 
neuroendocrine tumours) with gonadal, adrenal, renal and thyroid neoplasms. 
 
An equivalent hereditary disorder has not been proven in animals, though several studies report 
concurrent neoplasms/hyperplasias arising from diverse endocrine tissues, which may be 
functional or non-functional (Reusch, 2015): 
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- Medullary thyroid carcinoma, phaeochromocytoma, parathyroid hyperplasia, and bilateral 
interstitial cell testicular tumours (compares to MEN2 syndrome) (Peterson, Randolph, Zaki, 
& Heath, 1982); 
- Parathyroid tumour and phaeochromocytoma (Wright et al., 1995); 
- PDH and phaeochromocytoma; ADH (adrenal-dependent hyperadrenocorticism) and 
phaeochromocytoma (von Dehn et al., 1995); 
- Pituitary adenoma (with PDH) and phaeochromocytoma (Bennett & Norman, 1998); 
- Pituitary tumour with malignancy features and ACTH-positive (causing PDH), right 
adrenal with AT, and left adrenal with 2 ATs and phaeochromocytoma (causing ADH) 
(Thuróczy et al., 1998);  
- Parathyroid adenoma and PDH (compares to MEN1 syndrome) (Walker, Jones, Guildford, 
Burbidge, & Alley, 2000); 
- Insulinoma,  bilateral adrenocortical carcinomas, and aortic paraganglioma (Kiupel, 
Mueller, Ramos Vara, Irizarry, & Lin, 2000); 
- Pancreatic islet cell somatostatinoma, and gastrinoma in the mesenteric lymph nodes and 
liver (Hoenerhoff & Kiupel, 2004); 
- Thyroid carcinoma, adrenocortical carcinoma, and bilateral interstitial cell testicular 
adenomas (Proverbio et al., 2012); 
- Medullary thyroid carcinoma, bilateral phaeochromocytomas, and parathyroid adenoma 
(compares to MEN2 syndrome) (Arias, Castillo, Trigo, & Caneda Aristarain, 2016); 
- Parathyroid chief cell adenoma and bilateral phaeochromocytomas (Arias, Castillo, & 
Trigo, 2017). 
 
A recent study suggests that the prevalence of concurrent endocrine neoplasias in animals might 
be higher than previously thought (Beatrice et al., 2018). The reported prevalence of concurrent 
endocrine neoplasias was 2.1% in dogs and 1.3% in cats, with the adrenal glands being the most 
common organ to be affected in dogs. In this species, the most frequent combination of 
endocrine tumours and/or hyperplasias involved multiple concurrent adrenal gland lesions with 
ACTH-positive pituitary adenomas. However, the notion of MEN-like syndromes, as described 
in human medicine, were found extremely rare in dogs and cats. 
In sum, concurrent endocrine neoplasias has been proven to be more common than previously 
believed and it is only likely to be increasingly reported in light of an ageing patient population, 
advancement of veterinary medical care, and augmented clinician awareness (Galac & Grinwis, 
2018). Therefore, it might be important to undertake comprehensive assessments in face of an 
endocrine tumour diagnose, in order to be able to make adjustments to the treatment plan and 
to provide in-depth expectations to the owners (Galac & Grinwis, 2018; Reush, 2015). 
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1.2 Signalment 
1.2.1 Adrenocortical tumours 
Canine ADH affects middle-aged and older individuals (Anderson et al., 2001; Barrera et al., 
2013; Behrend, 2015; Kyles et al., 2003; Reusch & Feldman, 1991; van Sluijs et al., 1995). In 
an earlier study, the age of dogs with adrenocortical tumours varied between 6 to 16 years old 
(mean 11.3 ± 2.3 years) and, despite inexistence of significant difference in comparison with 
the group of PDH dogs (mean 10.4 ± 3.2 years), it seemed that animals with ADH tended to be 
older than those with PDH. This is, a larger proportion of dogs with ATs (92.5%, 37/41) were 
9 years of age or older, in contrast to dogs with PDH (77%, 34/44) (Reusch & Feldman, 1991). 
Both cortical adenomas and carcinomas are more frequently seen in old dogs (8 years and older) 
(Rosol & Gröne, 2016). Accordingly, Reusch & Feldman (1991) reported a mean age of 11.4 
± 2.1 years old for the adenoma group and 11.1 ± 2.3 years old for the carcinoma group. Later 
on, Barrera et al. (2013) described similar results. 
No gender predisposition has been established (Behrend, 2015); in spite of diverse studies 
(concerning ATs and PDH) contributing to an apparent overrepresentation of females 
(Anderson et al., 2001; Gallelli, Cabrera Blatter, & Castillo, 2010; Kyles et al., 2003; Reusch 
& Feldman, 1991; van Sluijs et al., 1995). For instance, in the study by Reusch & Feldman 
(1991), 63% and 57% of individuals with ATs or PDH, respectively, were females. Yet, others 
found no significant difference between the sex distribution of dogs with HAC and the general 
population (Ling, Stabenfeldt, Comer, Gribble, & Schechter, 1979 cited by Behrend, 2015); 
and, in another study, females were not even the majority (Hess, Kass, & Ward, 1998 cited by 
Behrend, 2015). 
Virtually every breed has been reported with PDH and ATs, with frequent association of 
German Shepherd, Labrador Retriever, and Terriers to functioning adrenocortical adenomas or 
carcinomas (Behrend, 2015). However, for HAC overall, a breed predilection has only been 
proven for Poodles, Dachshunds, and Boxers (Ling et al., 1979), and no difference was found 
in expression of the disorder between purebred and mixed-breed dogs (Bellumori, Famula, 
Bannasch, Belanger, & Oberbauer, 2013). 
Weight-wise, PDH may seem more common in smaller dogs (77% weighted < 20 kg) in 
comparison to ATs (46% weighted > 20 kg) (Reusch & Feldman, 1991). With regard to ATs in 
particular, Anderson et al. (2001) described a weight range from 4 to 51 kg (median 20 kg). 
Moreover, Barrera et al. (2013) reported a mean weight of 22.8 kg (16.1 to 29.5 kg) and 25.5 





Wide age ranges have been reported in the 2 largest case series of dogs with 
phaeochromocytomas: 3 to 15 years old (mean and median 10.5 years) (Gilson, Withrow, 
Wheeler, et al., 1994); 1.6 to 18 years old (mean 12 ± 2.8 years) (Barthez et al., 1997). Despite 
having been reported at practically every age, middle-aged to older animals are more commonly 
affected (Barrera et al., 2013; Barthez et al., 1997; Gilson, Withrow, Wheeler, et al., 1994; 
Herrera et al., 2008; Kyles et al., 2003; Reusch, 2015). 
No gender predisposition exists, neither between male and female, nor between entire and 
neutered dogs (Barthez et al., 1997; Gilson, Withrow, Wheeler, et al., 1994; Reusch, 2015). 
Likewise, and despite apparent overrepresentation of certain breeds (namely, Golden and 
Labrador Retriever, Boxer, Doberman, German Shepherd, Poodle, and Terriers) which might 
well result from their popularity, there is no clear breed predilection and more than 40 breeds 
have been reported (Barthez et al., 1997; Gilson, Withrow, Wheeler, et al., 1994; Reusch, 2015). 
Finally, in terms of weight, Barthez et al. (1997) observed a mean weight of 22.3 ± 11.6 kg. In 
posterior investigations, Herrera et al. (2008) described a weight range from 9 to 62 kg (median 
22.5 kg), while Barrera et al. (2013) observed a mean weight of 29.3 kg (24.5 to 34.1 kg). 
 
1.3 History, Clinical signs and Physical examination 
The clinical presentation generated by an adrenal neoplasm may be diverse, depending 
primarily on the tumour functionality. Inherently, producing tumours result in clinical 
manifestations caused by the pathophysiologic effects of the released substances. Accordingly, 
non-functional neoplasms are typical incidental discoveries (incidentaloma). However, in the 
later course of the disease, these endocrine-inactive tumours may similarly result in clinical 
signs caused by space-occupying effects, invasive nature of the tumour, rupture, and/or 
metastases (Arenas, Pérez-Alenza, & Melián, 2013). 
 
1.3.1 Adrenocortical tumours 
With regard to ADH, expected duration and type of clinical signs are similar to those observed 
with PDH (Behrend, 2015). The ACVIM (American College of Veterinary Internal Medicine) 
Consensus Statement for the Diagnosis of Spontaneous Canine Hyperadrenocorticism 
(Behrend, Kooistra, Nelson, Reusch, & Scott-Moncrieff, 2013) sums up the associated clinical 
manifestations, categorising them by frequency (Table 1). Additionally, the Panel points out 
that, in the present days, the signs reported are subtler and fewer as a result of increased 
awareness and consequential earlier detection of the disease. Also, care should be taken to avoid 
over diagnose HAC, pursuing it only if one or more of the common clinical signs and physical 
examination features are consistently identified (Behrend et al., 2013). On the contrary, the 
 11 
likelihood of HAC decreases in the presence of unrelated manifestations, such as, vomiting, 
diarrhoea, coughing, sneezing, pain, or bleeding (Behrend, 2015). 
Whereas clinical signs may vary between patients, and from subtler to dramatical, the clinical 
presentation typically progress slowly, with the uncommon possibility of entering intermittent 
phases of remission (Behrend, 2015; Peterson, Gilbertson, & Drucker, 1982). Acute, life-
threatening presentations attributed to ADH typically result from either pulmonary 
thromboembolism (PTE) or, rarely, tumour rupture (addressed in the following subsection – 
1.3.2) (Behrend, 2015). 
 
Table 1. Clinical manifestations of HAC and respective frequency at initial presentation. 
(Adapted from: Behrend, E.N., Kooistra, H.S, Nelson, R., Reusch, C.E., & Scott-Moncrieff, 
J.C. (2013). Diagnosis of Spontaneous Canine Hyperadrenocorticism: 2012 ACVIM Consensus 
Statement (Small Animal). J Vet Intern Med, 27: 1293.) 

























In dogs, ADH typically results from cortisol-producing ATs – the most common functional 
type of ATs (Reusch, 2015). Yet, as previously mentioned, other hormones (aldosterone, sex 
steroids, precursors) can be secreted ever so rarely1: in singularity (Gójska-Zygner et al., 2012; 
Johnson et al., 2006; Reine et al., 1999; Rijnberk et al., 2001; Syme et al., 2001) or along with 
other cortical steroids which, evidently, may create confusing clinical presentations due to the 
mixture of clinical signs (Behrend et al., 2005; Davies et al., 2008; Frankot et al., 2012; Machida 
et al., 2008). Likewise, puzzling presentations may arise from the coexistence of an AT with a 
phaeochromocytoma (Hylands, 2005; von Dehn et al., 1995). 
 
1.3.2 Phaeochromocytomas 
Phaeochromocytomas may generate highly diverse clinical manifestations depending on the 
causal nature of the clinical signs (Table 2). Functionally-active medullary tumours secrete 
catecholamines in an intermittent episodic manner, which means physical examination findings 
will be in accordance with the secretory activity of tumour at the time of presentation and 
                                                      
1 In consideration of their rarity, these will not be explored in-depth here. Readers are directed to the citations. 
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explains why these findings are often unremarkable. The causes behind the triggering of 
catecholamine release are generally undetermined. The episodes may fluctuate in: clinical 
presentation (certain signs may be continuously present, others may be added transiently, and 
unremarkable presentations may be noted between episodes); frequency (multiple times per 
day/week or spaced by numerous weeks/months – the longer the interval, the harder is to 
perceive the inherent connection between the episodes); severity (mild to potentially lethal; 
similar to previous episodes or, usually, exhibiting gradual progression); time period until first 
presentation to the veterinarian (from hours to years). Further difficulties may be encountered 
due to concurrence of other more common and worrisome illnesses, which are expected in 
patients of advanced age and stand out more than the phaeochromocytoma itself. Moreover, the 
wide variability and non-specific nature of clinical signs would be cause for raising suspicion 
of a phaeochromocytoma very often, virtually every day. Even though encountering a 
phaeochromocytoma is a rare event, it should be kept in mind that it is still missed quite 
frequently as a result of poor awareness. Phaeochromocytomas may also produce acute, life-
threatening situations generated by either a massive catecholamine surge that leads to collapse 
and sudden death, or by tumour rupture (Reusch, 2015). 
 
Table 2. Clinical signs in dogs with phaeochromocytomas divided by cause-related categories. 
(Adapted from: Reusch, C. E. (2015). Pheochromocytoma and Multiple Endocrine Neoplasia. 
In E. C., Feldman, R.W., Nelson, C. E., Reusch & J. C. R., Scott-Montcrieff (Eds.): Canine and 
Feline Endocrinology, (4th ed.), (p. 528). Missouri: Saunders, Elsevier.) 
























Anorexiab, weight lossb, lethargya 
 
Tachypnoeaa, dyspnoea, pantinga, tachycardiab, 
arrhythmiasb (mostly tachyarrhythmias), collapsea, 
pale mucus membranes, nasal/ocular/gingival 
haemorrhages, acute blindness 
 
Weaknessa, anxiety, pacing, disorientation, muscle 
tremor, seizures 
 
PU/PDb, vomitingb, diarrhoea, abdominal 
enlargement, abdominal painb 
 
Abdominal enlargement, ascites, abdominal pain, 
hind limb oedema 
 
Acute severe lethargy, painful abdomen, tachypnoea, 
weakness, collapse, tachycardia, pale mucus 
membranes, prolonged CRT 
 
To brain: seizures and other CNS signs; To vertebral 
canal or bone: tetraparesis, paraparesis, lameness, 
swelling, local pain 
Caption: a=the most common; b=others frequently encountered; 
PU/PD=polyuria/polydipsia; CRT=capillary refill time; CNS=central nervous system. 
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Note that the signs described in Table 2 caused by a large mass, local invasion, tumour rupture, 
or metastases, may be compatible with any type of malignant adrenal tumour (cortical or 
medullar; functional or non-functional), though benign neoplasms may also grow substantially 
resulting in mass-occupying effects and/or rupture (Behrend, 2015; Lang et al., 2011; Tursi, 
Iussich, Prunotto, & Buracco, 2005). Metastases-related clinical signs will naturally depend on 
the organs/structures affected. Traumatic and non-traumatic rupture of adrenal tumours  
resulting in intraabdominal or retroperitoneal bleeding is rather rare, accounting for 20 reported 
cases, and represent both medical and surgical emergencies (Barrera et al., 2013; Evans, 
Hosgood, Boon, & Kowalewich, 1991; Lang et al., 2011; Santamarina et al., 2003; 
Vandenbergh et al., 1992; Whittemore et al., 2001; Williams & Hackner, 2001). 
 
1.4 Diagnostic testing 
1.4.1 Basic bloodwork, Urinalysis and Blood pressure measurement 
Routine diagnostic workup includes complete blood count, serum biochemistry, urinalysis, 
urine protein : creatinine ratio, and blood pressure (BP) measurement. 
 
 1.4.1.1 Adrenocortical tumours 
Together with hypertension, the laboratory abnormalities enumerated in Table 3 are consistent 
with HAC and reinforce the diagnosis, provided that common clinical features (reviewed in 
Table 1) are identified as well from history and physical examination. However, HAC cannot 
be excluded solely on the basis of results within the reference ranges obtained on these profiles 
(Behrend et al., 2013). 
 
Table 3. Common abnormal laboratory findings associated with HAC. (Adapted from: 
Behrend, E.N., Kooistra, H.S, Nelson, R., Reusch, C.E., & Scott-Moncrieff, J.C. (2013). 
Diagnosis of Spontaneous Canine Hyperadrenocorticism: 2012 ACVIM Consensus Statement 
(Small Animal). J Vet Intern Med, 27: 1293.) 















Indicators of UTI 
 
Caption: CBC=complete blood count; ALKP=alkaline phosphatase; 





No consistent alterations are found in the basic screenings with capability to support the 
presumptive diagnosis of a phaeochromocytoma (Reusch, 2015). Reusch (2015) combines the 
laboratory abnormalities reported in the literature with their own findings on their canine 
population presenting with phaeochromocytomas, excluding animals with coexisting endocrine 
neoplasias – the irregularities encountered are listed in Table 4. Note that normal laboratory 
results have also been reported in these dogs. 
Likewise, hypertension is not a consistent finding, probably due to its cyclic nature. Besides, 
its presence is not specific for phaeochromocytomas – it is also often seen with HAC. Yet, the 
higher the systolic blood pressure, the higher the chance of dealing with a phaeochromocytoma 
(e.g., so far, a systolic BP over 300 mm Hg has solely been registered in dogs with 
phaeochromocytomas) (Reusch, 2015). 
 
Table 4. Reported laboratory abnormalities in dogs with phaeochromocytomas (Reusch, 2015). 
CBC Serum biochemistry Urinalysis 

























Caption: CBC=complete blood count; ALKP=alkaline phosphatase; ALT=alanine 
transaminase; AST=aspartate transaminase; BUN=blood urea nitrogen. 
 
1.4.2 Functional testing 
Because the findings gathered from history, physical examination, imaging, and routine 
laboratory profiles might be similar between dogs with phaeochromocytomas and those with 
ADH (e.g., weakness, tachypnoea, panting, PU/PD, hypertension, identification of an adrenal 
mass, raised alkaline phosphatase, alanine transaminase, and cholesterol, hyposthenuric or 
isosthenuric urine), it makes sense to test for ADH first in respect of their higher frequency 
relatively to phaeochromocytomas (Reusch, 2015). 
Note that even more puzzling scenarios can arise from concurrence of HAC (PDH or ADH) 
with phaeochromocytomas, which have been reported (Bennett & Norman, 1998; Hylands, 
2005; Lang et al., 2011; Oblak et al., 2016; Thuróczy et al., 1998; van Sluijs et al., 1995; von 
Dehn et al., 1995). 
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1.4.2.1 Adrenocortical tumours 
For a suspected producing-AT, a variety of individual or combinations of tests are routinely 
used to diagnose HAC and differentiate PDH from ADH: UCCR (urinary corticoid : creatinine 
ratio), ACTHST (ACTH stimulation test), LDDST/HDDST (low/high dose dexamethasone 
suppression test), eACTH (endogenous ACTH) measurement. As no assay is 100% accurate, a 
combination of tests is sometimes required to get to the bottom of the matter. Furthermore, 
interpretation of differentiating tests is only viable if the HAC diagnosis has been already 
confirmed on a screening test (Behrend, 2015). 
UCCR is a sensitive test to detect cortisol hypersecretion and therefore useful to rule out HAC 
(Behrend, 2015; Behrend et al., 2013). For instance, it might be particularly handy when an 
adrenal incidentaloma is encountered and clinical examination suggests a non-functional 
lesion. The contrary, i.e., rule in HAC, is unattainable due to the low specificity of the assay. 
Reported sensitivity and specificity for the diagnosis of HAC ranges from 75-100% and 20-
25%, respectively, when a single, random urine sample is collected in veterinary hospitals 
(Behrend, 2015; Behrend et al., 2013). To minimise false-positive results, it is advisable to 
collect a urine sample at home with a minimal interval of 2 days after a visit to the veterinary 
practice (Behrend et al., 2013). Apart from the low specificity, other drawback of UCCR is its 
inability to differentiate between PDH and AT on its own (Behrend, 2015).  
The ACTHST is a specific test for the diagnosis of HAC, thus useful to rule it in. While the 
reported sensitivity for dogs with HAC caused by and AT in particular ranges from 57-63%, 
overall specificity varies from 59-93% (Behrend et al., 2013). Shortcomings include: primarily 
a lower sensitivity than the LDDST, especially for dogs with an AT; inconclusive results when 
post-ACTH values fall within a grey range zone; and not being able to discriminate between 
PDH and AT on its own (Behrend, 2015). Moreover, results should be interpreted carefully. 
For instance, while the detection of an adrenal mass by means of imaging techniques along with 
an ACTHST consistent with HAC would point towards ADH, case reports of concurrent 
PDH/pituitary tumours and ATs have been described (Greco et al., 1999; Oblak et al., 2016; 
Thuróczy et al., 1998). Interestingly, in one study dogs with carcinomas had higher responses 
to the test than those with adenomas (Peterson, Gilbertson, et al., 1982), however, no consistent 
differences were noted in another (Feldman, 1983 cited by Behrend, 2015). 
Because cortisol-secreting neoplasms are the most frequent hormonally-active ATs, the typical 
ACTHST measures cortisol response. Yet, normal or subnormal ACTHST results accompanied 
by clinical manifestations strongly suggestive of HAC can be uncommonly encountered. In 
these situations, it is possible that other hormones are being secreted which can be measured 
instead of cortisol: sex steroids (e.g. progestins) (Norman et al., 1999; Ristic et al., 2002; Syme 
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et al., 2001) or cortisol intermediates (e.g. corticosterone) (Behrend et al., 2005; Frankot et al., 
2012). Progestins and cortisol intermediates may interact with glucocorticoid receptors, thus 
resulting in HAC-associated clinical signs, inhibition of the pituitary gland to release ACTH, 
atrophy of the normal adrenal cortical parenchyma, and in the drop of endogenous cortisol 
concentrations (Behrend, 2015). Furthermore, in the presence of clinical evidence of 
mineralocorticoid excess other hormones may equally be measured through an ACTHST, such 
as, aldosterone (Frankot et al., 2012; Johnson et al., 2006; Machida et al., 2008) or steroid 
precursors (e.g. deoxycorticosterone) (Davies et al., 2008; Reine et al., 1999). 
The LDDST stands out for its high sensitivity, being the screening test of choice for 
spontaneous HAC, and for its ability to potentially discriminate between PDH and AT. 
Reported sensitivity and specificity varied from 85-100% and 44-73%, respectively (Behrend 
et al., 2013). Remarkably, the overall sensitivity was roughly 95%, when numerous previous 
reports are combined (Behrend & Kemppainen, 2001). Demerits include a lower specificity 
(affected by non-adrenal disorders and possibly stress) and being a lengthy assay (needs 8h to 
be concluded) (Behrend et al., 2013; Kaplan, Peterson, & Kemppainen, 1995; May, Frank, 
Hnilica, & Lane, 2004). In addition, occurrence of an “inverse pattern” (i.e., cortisol 
concentration increased at 4h and suppressed at 8h post-dexamethasone) is non-diagnostic but 
highly suspicious of HAC – warrants further testing (Behrend et al., 2013). 
LDDST and HDDST share many of advantages and disadvantages, namely their role as 
differentiation tests (Behrend, 2015). However, none can be considered 100% absolute. While 
the lack of suppression at 8h post-dexamethasone (i.e., increased cortisol concentration above 
the laboratory reference cut-off) supports a HAC diagnosis, the 4h value holds the key for 
differentiation: suppression likely confirms PDH – pattern seen in ~75% of dogs with PDH; 
little to no suppressive effect renders the test inconclusive – pattern seen in all dogs with ATs 
independently of dexamethasone dosage and in ~25% of dogs with PDH. If no suppression is 
seen on a LDDST, an HDDST will only offer differentiation in about 12% additional cases of 
PDH. For this reason, it is preferable to opt for an assessment of eACTH or abdominal 
ultrasound (Behrend et al., 2013). 
Measurement of eACTH is the most accurate standalone biochemical test with ability to 
definitively differentiate PDH from AT. Whereas dogs with PDH would be expected to have 
normal to elevated eACTH concentrations (secreted by a pituitary tumour), those with ADH 
would present below normal values (as a result of the negative feedback exerted by the 
autonomous AT secretion of cortisol) (Behrend, 2015). Yet, it should be noted that this is not 
an appropriate assay for the screening of HAC, considering that healthy dogs and those with 
PDH have similar concentrations of eACTH (Hanson, Kooistra, Mol, Teske, & Meij, 2006). 
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The assay’s accuracy for differentiation depends on the analytical sensitivity (poor sensitivity 
is the most common concern with some assays) and working range (namely, poorly at the lower 
end) of the analyser/technique. Some dogs with PDH have eACTH concentrations at or below 
the sensitivity of the test, i.e., what the assay can measure accurately. The chance of obtaining 
falsely low value results in dogs with PDH increases with intra- and inter-assay variability 
(especially at lower eACTH concentrations), episodic ACTH release, and with inadequate 
sample handling in consideration of inherent eACTH lability (Behrend et al., 2013). 
A combination of tests can be useful in allowing both screening and differentiation, for instance, 
UCCR and HDDST; ACTHST and HDDST (Behrend et al., 2013). 
 
1.4.2.2 Phaeochromocytoma 
Biochemical testing for the diagnosis of phaeochromocytomas in dogs has only recently started 
its evolution process in veterinary medicine as result of poor medical awareness, limited 
availability of assays, absence of species-specific reference ranges, and impracticality 
associated with 24-hour urine collections in client-owned dogs (difficult task on its one; 
demanding sampling and conditioning for shipment requirements; implicates postponing 
medical therapy with phenoxybenzamine, which is known from humans to be a possible cause 
of false-positive results) (Reusch, 2015). 
Taking into account the already mentioned inconveniences, the urine assays began to be studied 
on the basis of single-voided samples with results expressed as ratios to the urinary creatinine 
in the same sample, and timing and setting of collection were investigated as possible 
influencing aspects to consider (namely, in regard of the stress associated with veterinary care 
and hospital environment) (Kook, Boretti, Hersberger, Glaus, & Reusch, 2007). Significant 
higher epinephrine-, norepinephrine-, and metanephrine-to-creatinine ratios were found in 
samples taken in the hospital compared to those taken 7 days after discharge, from healthy 
client-owned dogs; however, these differences were relatively small and normetanephrine 
ratios did not differ. Furthermore, a similar evaluation made in another study did not find 
difference in any of the parameters (Quante et al., 2010). Hence, collection of urine samples in 
the hospital has been reported as a standard approach (Reusch, 2015). 
Dogs with phaeochromocytomas have been reported to have significantly higher urinary 
catecholamines, and normetanephrine ratios compared to healthy dogs (Kook, Grest, Quante, 
Boretti, & Reusch, 2010; Quante et al., 2010; Salesov et al., 2015). 
Along with the already expose similarities between dogs with phaeochromocytomas or HAC, 
Quante et al. (2010) reported that approximately 50% of dogs with HAC also had statistical 
significant higher urinary catecholamines and normetanephrine ratios compared to healthy 
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dogs. These results serve as another reminder to bear HAC in mind as a differential diagnosis 
and to highlight the importance of identifying discriminative parameters/assays.  
Likewise, differentiation from non-adrenal diseases (NAD) is fundamental. It is possible that 
the greater the severity of illness, the higher the values obtained for urinary catecholamines and 
their metabolites (Cameron, Monroe, Panciera, & Magnin-Bissel, 2010). Therefore, it might be 
more difficult to interpret results in dogs with concurrent illnesses. 
In sum, several studies have demonstrated the superior performance of urinary normetanephrine 
over urinary catecholamines and metanephrine, namely for being the most sensitive and 
allowing the best differentiation between dogs with phaeochromocytoma, HAC, NAD, and 
healthy dogs, with the least overlap (Kook et al., 2007, 2010; Quante et al., 2010; Salesov et 
al., 2015). No overlap has been consistently detected between healthy dogs and those with 
phaeochromocytoma (Kook et al., 2010; Quante et al., 2010; Salesov et al., 2015). Yet, the 
same cannot be said between dogs with phaeochromocytoma and HAC. While in one study 
there was an overlap of results (Quante et al., 2010), in another there was not (neither between 
dogs with phaeochromocytoma and HAC, nor between those with NAD) (Salesov et al., 2015). 
Taking into consideration the results of the former, the authors of the latter study recognized 
that their results were most likely coincidental and possibly affected by sample size. 
To work around this adversity, cut-off values were defined. For instance, a cut-off urinary 
normetanephrine ratio of 4 times the upper limit of “normal” (measured in healthy dogs) 
permitted discrimination without overlap of values between dogs with phaeochromocytoma 
and those with HAC (Quante et al., 2010; Salesov et al., 2015). While this meant the test 
specificity was perfect, sensitivity would not as some phaeochromocytoma cases would have 
been overlooked. Sensitivity could benefit from lower cut-off values; however, specificity 
would be hurt. A gold standard method to determine the true function of the adrenal gland (e.g., 
cut-off of 4 times the urinary normetanephrine ratio of healthy dogs) remains to be defined 
(Salesov et al., 2015). 
Whereas in urine only total normetanephrine and metanephrine (free and sulfoconjugated) are 
measured, in plasma total and free can be measured. Alike the urine assay, plasma-total and 
plasma-free normetanephrine have also proven to be diagnostically superior over plasma 
catecholamines and metanephrine, allowing discrimination of dogs with phaeochromocytoma 
from those with ATs/HAC, NAD, and healthy dogs, with nearly no overlap (Gostelow, Bridger, 
& Syme, 2013; Salesov et al., 2015).  
Although in one study the inexistence of overlap of values for the urinary normetanephrine 
assay seemed to merit superiority to the test in comparison to the corresponding plasma assay 
(Salesov et al., 2015), as previously argued, the authors themselves viewed it just to be a matter 
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of coincidence, as an overlap in the urinary assay had been previously found in another study 
(Quante et al., 2010). Therefore, currently, both urine and plasma assays have similar 
acceptable performances, leaving the choice between one of the two dependent upon 
availability of technical facilities, as well as, of dog-specific reference ranges (values are much 
higher than in humans) (Gostelow et al., 2013; Salesov et al., 2015). The diagnosis of 
phaeochromocytoma should be based on the separated measurement of metanephrines 
(normetanephrine and metanephrine). The major difficulty with these tests will be patients with 
smaller tumours because of their likely lower levels. Special consideration of sampling and 
conditioning for shipment requirements is imperative as they might represent key influencing 




Radiography may contribute to back-up the suspicion of HAC. However, because all thoracic 
and abdominal findings are non-specific and rather rare, it cannot be solely used to confirm the 
diagnosis of HAC or to differentiate between PDH, ADH, other endocrine conditions (e. g., 
diabetes and hypothyroidism), and obesity (Behrend, 2015; Schwartz, Störk, Mellor, & 
Sullivan, 2000). Radiographic alterations consistent with HAC include abdominal 
distension/pendulous abdomen, good contrast as result of abdominal fat deposition (primarily 
omental), hepatomegaly, bladder distension, osteopenia, mineralisation of the perihilar bronchi 
and pulmonary interstitium, as well as, of dermal and subcutaneous tissues in areas prone to 
calcinosis cutis (Behrend, 2015; Behrend et al., 2013; Berry, Hawkins, Hurley, & Monce, 2000; 
Schwartz et al., 2000). Furthermore, in the event of PTE, plain thoracic radiographs will most 
commonly demonstrate an alveolar or alveolar interstitial pattern in one or multiple areas 
(Flückiger & Gomez, 1984; Goggs, Benigni, Fuentes, & Chan, 2009). 
ATs can be visualised either due to mass-effect or calcification within the neoplasm (Behrend 
et al., 2013; Penninck, Feldman, & Nyland, 1988; Reusch & Feldman, 1991), although 
mineralisation is not tumour-specific and may also occur with PDH-induced hyperplastic 
glands less commonly  (Grooters, Biller, Theisen, & Miyabayashi, 1996; Penninck et al., 1988). 
Still, many ATs can be missed, and that is why radiography does not allow exclusion of the 
diagnosis. In one study, only 56% of 23 dogs with functioning ATs had radiological evidence 
of adrenomegaly with or without calcification; besides, mineralisation of the adrenal did not 
permit to discriminate between adenoma and carcinoma (Penninck et al., 1988). Similar results 
were reported by Reusch & Feldman (1991), who also observed inferior radiographic detection 
of right-sided carcinomas. Bilateral tumours may also be overlooked (Ford et al., 1993; Reusch 
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& Feldman, 1991). Ultimately, tumours measuring  20 mm in diameter are unlikely to be 
visualised (Voorhout, Rijnberk, Sjollema, & van den Ingh, 1990 cited by Behrend, 2015). 
In dogs with phaeochromocytomas, abdominal radiographs add limited value and, similarly to 
ATs, difficulties may be encountered (e.g., sufficient size of the mass to be detectable, rarity of 
mineralisation in medullary masses). Yet, identifiable neoplasms may show as soft tissue 
opacities in close relation to the kidney, with or without displacement/distortion/obscuration of 
the ipsilateral kidney or near-by structures. Other radiographic findings observed in dogs with 
phaeochromocytomas included loss of serosal detail as result of abdominal effusion or diffuse 
retroperitoneal soft tissue radiopacity due to haemorrhage from a ruptured tumour, enlarged 
CVC, hepatomegaly, generalised cardiomegaly, ventricular enlargement, and pulmonary 
oedema (Barthez et al., 1997; Gilson, Withrow, Wheeler, et al., 1994; Reusch, 2015). 
Finally, radiography plays an important role as a part of the preoperative investigations prior to 
removal of any adrenal tumour. Three-view thoracic radiographs constitute a suitable method 
of searching for lung metastases, which appear as soft tissue nodules (Barthez et al., 1997; 
Behrend, 2015; Gilson, Withrow, Wheeler, et al., 1994; Reusch & Feldman, 1991). However, 
this finding has not been commonly encountered at diagnosis/preoperative assessment in 
several studies (Anderson et al., 2001; Arenas et al., 2013; Barrera et al., 2013; Jiménez-Peláez, 
Bouvy, & Dupré, 2008; Kyles et al., 2003; Lang et al., 2011; Massari et al., 2011; Oblak et al., 
2016; Schwartz et al., 2008). For ruling out abdominal metastases radiography is not ideal, 
thought it may raise suspicion of rather evident lesions such as, for instance, hepatic masses 
(Reusch, 2015; Reusch & Feldman, 1991). 
 
1.4.3.2 Ultrasonography 
Abdominal ultrasound (US) allows identification of both adrenal glands by experienced 
practitioners, recognition of smaller and non-mineralised adrenal tumours, retroperitoneal 
effusion, tumour invasion into vessels and adjacent structures, as well as, of intraabdominal 
metastases – all of the above are verified with higher resolution and precision. Nonetheless, 
ultrasonographic examination may be difficulted by presence of gas in the gastrointestinal tract, 
large body size, obesity, abdominal lymphadenopathy or masses, renal mineralization, or liver 
disease (Behrend, 2015; Reusch, 2015). 
Size-wise, the measurements obtained by this imaging technique underestimates the actual size 
of the adrenal glands (Behrend, 2015; Pagani et al., 2016). Depending on the alignment of the 
adrenal glands’ long axis, cross-sectional oblique views can result in miscalculated dimensions. 
The US cut-off value of 7.4 mm for the normal maximum diameter of the larger of the cranial 
or caudal pole, in sagittal or transverse planes, independently of body weight, has been 
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frequently used and is the most widely accepted (Behrend, 2015). A recent  study has also 
reported that the caudal pole thickness of both left and right adrenals is the best parameter for 
ultrasonographic evaluation of normal and pathological adrenal glands size in dogs (Pagani et 
al., 2016). 
On US images, features consistent with an adrenal tumour include moderate asymmetry within 
and/or between glands, distortion of normal parenchymal architecture, and contralateral gland 
cortical atrophy (in case of a secreting-AT) (Behrend et al., 2013). Other neoplastic 
characteristics have great variability: shape (focal, minimal-disrupting nodules or diffuse 
masses obviously altering the gland’s figure) and echogenicity (hypo-, iso-, or hyperechoic 
relatively to the renal cortex; and homo- or heterogenous). Mineralisation (hyperechoic areas 
with acoustic shadowing), necrosis or haemorrhage (an-, hypo- or isoechoic areas) can be 
present as foci (Besso, Penninck, & Gliatto, 1997; Hoerauf & Reusch, 1999). 
Ambiguity arises when mild asymmetry between glands is encountered, as it may also be 
deceptively found in dogs with PDH. Yet, ADH (main form of ACTH-independent HAC) can 
be appropriately diagnosed with US when the maximal dorsoventral thickness of the smaller 
gland (SDV) is ≤ 5.0 mm, with 82-100% sensitivity and 82-99% specificity (95% confidence 
interval) for that same cut-off value. Hence, secreting-ATs and equivocal asymmetric 
hyperplasia, occasionally observed with ACTH-dependent HAC  (mainly PDH), can be 
differentiated (Benchekroun et al., 2010). 
For detection of a tumour thrombus within the CVC, US has been reported to be 100% sensitive 
and 96% specific. However, if all forms of vascular invasion were to be considered (i.e., 
including vascular wall invasion without coexistent thrombus), sensitivity and specificity 
would be altered to 76% and 96%, respectively (Davis, Schochet, & Wrigley, 2012). 
Accordingly, another study reported a sensitivity of 80% and a specificity of 90% (Kyles et al., 
2003). This can be explained by the difficulty in discriminating mural compression from actual 
vascular invasion (into the vessel wall or as a tumor thrombus) and a blood clot (“true” 
thrombus), when using this imaging method. Furthermore, identification of thrombi confined 
to the phrenicoabdominal vein might be challenging due to the small caliber nature of the vessel 
(Reusch, 2015). 
US is also a suitable screening test for recognition of intraabdominal metastatic lesions, namely 
in the liver (Reusch & Feldman, 1991). Confirmation can be obtained through 
ultrasonographic-guided aspiration/biopsy (Behrend, 2015). 
Shortcomings of this imaging method include: occasional undetectability of contralateral 
adrenal atrophy to a functional AT (Hoerauf & Reusch, 1999); inability to discern between 
macronodular hyperplasia from an AT; and possible misleading presentations such as 
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identification of bilateral tumours which may deceptively point towards a PDH diagnosis 
(Behrend, 2015). 
Additionally, being able to infer on tumour origin or behaviour with US is improbable, 
especially in earlier stages, unless obvious features attributed to malignancy (local or distant 
invasion) are perceived. No pattern of echogenicity or architecture is specific, and even 
mineralization (which occurs more frequently within cortical masses rather than medullar) 
cannot be used as a differentiating factor in an individual patient (Besso et al., 1997). 
Ultimately, size can provide helpful guidance. An adrenal gland with a maximum diameter 
superior to 40 mm is highly correlated with malignancy (Behrend et al., 2013; Besso et al., 
1997). Moreover, any mass measuring ≥ 20 mm in maximum diameter or presenting signs of 
vascular invasion, deserves serious ponderation of malignancy (Cook et al., 2014; Labelle et 
al., 2004) and growth potential (Arenas et al., 2013). 
Interestingly, by means of contrast-enhanced ultrasonography (a modality of ultrasonography), 
it might be feasible to take conclusions towards tumour type and behaviour, for instance, using 
vascular patterns and contrast-enhancement features (Bargellini et al., 2016; Pey et al., 2014). 
 
1.4.3.3 Computed tomography and Magnetic resonance imaging 
In comparison to US, computed tomography (CT) provides a facilitated and superior 
assessment of tumour size, shape, architecture, and margination (Reusch, 2015). What is more, 
contrast-enhanced CT has been shown to accurately execute crucial preoperative 
determinations regarding canine adrenal masses, with 92% sensitivity and 100% specificity for 
detection of vascular invasion (into the phrenicoabdominal vein, venae cava, and renal vein). It 
was possible to correctly differentiate between mural compression and actual vascular invasion, 
as well as, to identify invasion into the local musculature (Schultz, Wisner, Johnson, & 
MacLeod, 2009). Likewise, a tumour thrombus and a blood clot may be reliably distinguished 
(Reusch, 2015).  
CT also improves the search for distant metastatic lesions (Behrend, 2015). Indeed, it was 
proven to be a more sensitive method for detection of pulmonary metastases than thoracic 
radiography (Armbrust et al., 2012).  
On CT images, adrenal tumours features may vary: attenuation (homo- or heterogeneous with 
cystic or mineral components); margins (smooth, lobular, irregular); contrast enhancement 
(heterogeneous, peripheral, mild) (Rosenstein, 2000; Schultz et al., 2009). Notably, this 
imaging method may reveal mineralization, masses with diameters ≤ 20 mm, and atrophy of an 
adrenal contralateral to a functional AT, that might have been missed by radiography or 
ultrasonography (Hoerauf & Reusch, 1999; Voorhout, Stolp, Rijnberk, & van Waes, 1990). 
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Still, even with its advantages, it might be tricky to distinguish unilateral nodular hyperplasia 
from an AT (Voorhout, Stolp, Lubberink, & van Waes, 1988). 
Interestingly, distinction of dogs with ACTH-independent HAC from those with ACTH-
dependent HAC can be conjectured on the basis of an adrenal gland diameter ratio > 2.08 on 
reformatted images, with 100% sensitivity and 98% specificity (95% confidence interval) for 
that same threshold value (Rodríguez Piñeiro et al., 2011). 
The level of accuracy and detail of CT findings provides valuable guidance when constructing 
a surgical plan, namely when opting for a particular surgical approach (e.g. midline or 
retroperitoneal) (Bailey, 1986; Emms, Wortman, Johnston, & Goldschmidt, 1986). 
Relatively to CT, magnetic resonance imaging (MRI) may be more accurate in establishing the 
exact cranial extension of the CVC thrombosis, like has been showed in human medicine 
(Goldfarb et al., 1990). However, use of MRI is still limited, primarily due to significant inferior 
availability. Other drawbacks include being more expensive and taking longer time to complete 
a scan (Reusch, 2015). 
In fact, in veterinary medicine, studies describing the systematic use of MRI as a method of 
assessment of adrenal lesions in dogs and cats are scarce. Yet, the appearance of supposed 
normal canine adrenal glands in MRI scans was reported (Llabres-Diaz & Dennis, 2003). MRI 
may prove useful as method of identification of metastases, namely when distant spread of a 
phaeochromocytoma to the central nervous system is present (Spall et al., 2011). Its modalities 
may also have the potential to infer on tumour behaviour (benign, malignant) and detect 
vascular invasion, in similarity to protocols used in human medicine (Larson et al., 2013). 
A variety of imaging techniques, including modalities of CT and MRI, have been use in human 
medicine to distinguish between types of adrenal tumours (cortical, medullar, metastatic) and 
to infer on malignancy (Blake, Cronin, & Boland, 2010; Fitzgerald, 2018; Leung, Stamm, Raja, 
& Low, 2013). In dogs, however, these investigations are taking its first steps. In one study, it 
was not possible to discriminate between tumour types as a result of the overlap of CT-
identified characteristics, though intratumoural localisation and transition of contrast 
enhancement was not evaluated (Gregori, Mantis, Benigni, Priestnall, & Lamb, 2015). Later 
on, another study has proven the worth of triple-phase helical CT, where specific characteristics 
were significant in differentiating between adrenocortical adenoma and carcinoma, and 
phaeochromocytoma (Yoshida et al., 2016).  
 
1.4.4 Incidental discovered adrenal mass 
The National Institutes of Health State-of-the-Science Statement (2002, p.4) National Institutes 
defines the term incidentaloma for human medicine: 
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Clinically inapparent adrenal masses are discovered inadvertently in the course of 
diagnostic testing for other clinical conditions that are not related to suspicion of 
adrenal disease and, thus, are commonly known as incidentalomas. The definition 
of incidentaloma excludes patients who undergo imaging procedures as part of 
staging and work-up for cancer. 
 
Over the past years, the use of US routinely has proven its key-role in the discovery of adrenal 
incidentalomas as predicted by Myers (1997), with a prevalence estimated at 4% and >80% of 
affected dogs being at least 9 years old (study period: 2007-2010) (Cook et al., 2014). An even 
higher prevalence (9.3%) was reported in a similar study using abdominal CT (study period: 
2013-2014) (Baum et al., 2016). While these findings may indeed represent early stages of a 
worrisome adrenocortical carcinoma or phaeochromocytoma, it is imperative that they are 
interpreted critically considering that these animals tend to be older, thus their likelihood of 
having age-related minor alterations in their adrenal glands (non-functional and -neoplastic, 
with less than 15 mm in diameter, affecting one pole of a gland with a normal contralateral), as 
well as, other concomitant diseases (inclusively, other neoplastic diseases) (Behrend, 2015). 
Upon this discovery, careful investigation of the nodule/masse endocrinological activity, 
behaviour (benign, malignant), and origin (cortical, medullar, metastatic) is warranted (Reusch, 
2015) (Table 5).  Aggressiveness of the diagnostic and therapeutic approach depends on diverse 
aspects: age of the patient; concurrent medical issues and respective severity; original motive 
that led to the US or CT scan; probability of the nodule/mass being or becoming hormonally 
active, grow considerably, and/or invade local or distant structures; and finally, the client’s 
wishes and willingness to take action (Behrent, 2015). 
 
Table 5. Major differential diagnoses of an incidentally discovered adrenal gland mass. 
(Adapted from: Reusch, C. E. (2015). Pheochromocytoma and Multiple Endocrine Neoplasia. 
In E. C., Feldman, R.W., Nelson, C. E., Reusch & J. C. R., Scott-Montcrieff (Eds.): Canine and 
Feline Endocrinology, (4th ed.), (p. 533). Missouri: Saunders, Elsevier.) 
 
Major differentials of an incidentally discovered adrenal mass 
Hormonally active adrenal nodule/mass 
> Aldosterone-producing adenoma, carcinoma, or hyperplasia 
> Glucocorticoid-producing adenoma or carcinoma 
> Adrenocortical hyperplasia 
> Sex-hormone producing adenoma or carcinoma 
> Phaeochromocytoma 
 
Hormonally inactive adrenal nodule/mass 
> Hormonally silent adenoma, carcinoma, or hyperplasia 
> Metastasis 
> Miscellaneous: myelolipoma, lipoma, cyst, abscess, hematoma, or granuloma 
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Although some of the differentials in Table 5 are no cause for concern, being able to identify 
those cases is highly difficult without histopathological examination. Even in the presence of 
small, non-functional nodules/masses (< 15-20 mm), it should be beared in mind that they might 
become functionally active with time and there might be a ~14-30% chance of an incidentaloma 
being malignant (Cook et al., 2014). Moreover, for any mass measuring ≥ 20 mm in maximum 
diameter, the likelihood of malignancy (Cook et al., 2014; Labelle et al., 2004) and growth 
potential (Arenas et al., 2013) might also be high. 
As such, it would be prudent to closely monitor these cases for growth and evolution, which 
can be easily accomplished with US. Behrend (2015) suggests starting intervals between scans 
of 2 to 3 months, which later can be extended to 4 to 6 months. If size increases considerably, 
pursuing surgical excision should be recommended. 
 
1.4.5 Fine-needle aspiration 
Cytological evaluation of specimens acquired by ultrasonographic-guided fine-needle 
aspiration/biopsy (US-FNA) of an adrenal nodule/mass may reveal or point towards its origin 
and malignancy potential. Particularly, it may have a valuable role in the investigation of 
adrenal incidentalomas of uncertain clinical significance, avoiding lengthy postponements in 
pursuing the ultimate definite treatment (i.e., adrenalectomy) (Sumner, Lacorcia, Rose, 
Woodward, & Carter, 2018). Furthermore, these findings allow an accordingly adjustment of 
preoperative planning, therefore minimising perioperative mortality (Behrend, 2015; Herrera 
et al., 2008). 
Indeed, a recent study showed that cytology may be as accurate as in 90 to 100% of cases in 
distinguishing cortical from medullary tumours in companion animals (Bertazzolo et al., 2014). 
Unfortunately, it was not reliable enough to judge tumour biological behaviour. 
In veterinary medicine, this diagnostic tool has been infrequently reported (Bertazzolo et al., 
2014; Besso et al., 1997; Rosenstein, 2000; Spall et al., 2011). Inherently, little is known 
regarding potential risks and complications associated with percutaneous US-FNA of adrenal 
lesions, though there is no reason not to extrapolate possibilities from human medicine literature 
(e.g., increased difficulty in surgical resection of the mass as a result of inflammation and 
retroperitoneal fixation, haematoma, error or inadequate biopsy, severe pain, severe 
hypertension due to triggering of a catecholamine surge, delay in pursuing the surgical 
procedure) (Besso et al., 1997; McCorkell & Niles, 1985; Reusch, 2015; Vanderveen et al., 
2009). Even so, in the previously cited veterinary case studies, no detrimental effects were 
encountered. 
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Very recently, in an attempt to provide clinical safety information regarding percutaneous US-
FNA of adrenal lesions, a study reported a complication rate of 5%, where only in 1 of 20 
separate uni- or bilateral sampling events, a dog develop a subsequent adverse reaction 
(ventricular tachycardia) – its cytological sample was consistent with a phaeochromocytoma 
(Sumner et al., 2018). Although this diagnostic instrument seemed to be relatively safe in this 
small study, further supportive investigations are required. 
 
2. TREATMENT OF ADRENAL GLAND NEOPLASMS 
2.1 Conservative management 
2.2.1 Adrenocortical tumours 
Medical therapy is generally reserved for patients to whom the risk of undertaking 
adrenalectomy does not outweigh the benefits to their welfare – those of very old age, 
debilitated, with deemed unresectable masses, metastases or concerning comorbidities – and 
when pursuing surgery is against owners wishes (Kintzer & Peterson, 1997; Lunn & Page, 
2013; Reusch, 2015). 
The primary choices for medical management are mitotane and trilostane. Mitotane is an 
adrenocorticolytic agent, causing selective necrosis of the zonae fasciculata and reticularis 
(Behrend, 2015).  Treatment with mitotane serves as a medical adrenalectomy by using it as a 
proper chemotherapeutic agent, aiming to obliterate all tumour tissue and even to cause 
hypoadrenocorticism (Kintzer & Peterson, 1997). Its effectiveness and relative safety was 
shown (Kintzer & Peterson, 1994). For this purpose, doses required are typically higher than 
those for PDH and still, relapses are common. Unfortunately, its effectiveness might be limited 
by adverse reactions to direct mitotane toxicity (e.g., anorexia, lethargy, weakness, diarrhoea), 
which prevent completeness of treatment (Kintzer & Peterson, 1997). 
Trilostane acts as an inhibitor of the adrenal enzyme 3β-hydroxysteroid dehydrogenase, thereby 
suppressing production of progesterone and its end-products (e.g., cortisol and aldosterone). 
While, theoretically, these effects should be fully reversible, adrenal necrosis can occur with 
consequential extended or perpetual cortisol deficiency with or without aldosterone deficiency. 
In terms of doses, the protocol is identical whether one is dealing with PDH or an AT (Behrend, 
2015). Even without adrenocortical cytotoxicity, trilostane has been associated with successful 
outcomes of patients with ADH (Eastwood, Elwood, & Hurley, 2003; Feldman, 2011; Vaughan, 
Feldman, Hoar, & Nelson, 2008), including dogs with metastases (Benchekroun et al., 2008). 
Two studies have compared trilostane and mitotane in dogs with ADH and reported median 
survival times of 353 and 102 days (Helm et al., 2011), respectively; and of 14.0 and 15.6 
months (Arenas, Melián, & Pérez-Alenza, 2014), respectively. In both studies, no significant 
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differences were detected between survival times. However, because the trilostane has milder 
and less frequent adverse effects, i.e., is less toxic, it is advisable to use trilostane primarily 
(Arenas et al., 2014). Evidence of metastases (Helm et al., 2011), old age, weakness, and high 
post-ACTH cortisol concentrations (Arenas et al., 2014) were found to be negative prognostic 
indicators with statistical significance. 
Ketoconazole can also be used as palliative therapy in light of its action as an inhibitor of 
adrenal and gonadal steroidogenesis through enzymatic blockade. Basically, it blocks cortisol 
production and rapidly decreases circulating concentrations. Therefore, ketoconazole may 
allow control of clinical signs (Feldman, Bruyette, Nelson, & Farver, 1990; Kintzer & Peterson, 
1997). Nevertheless, in contrast to mitotane, this alternative drug lacks adrenocortical 
cytotoxicity and would not be expected to act on tumour growth; rendering it to be a second-
line option (Kintzer & Peterson, 1997). 
Recently, a study evaluated the feasibility and efficacy of a modality of radiotherapy in treating 
canine adrenocortical tumours with vascular invasion (Dolera et al., 2016). Though promising, 
further investigations regarding treatment safety and efficacy are due. 
 
2.2.2 Phaeochromocytomas 
No successful chemotherapy or radiotherapy protocol has been reported in detriment of the 
surgical route (Lunn & Page, 2013; Reusch, 2015). Conservative management can solely 
manage clinical signs (namely, excessive circulating catecholamine-related), with no effect on 
other neoplastic evolutive behaviours (growth, local invasion, distant spread). Even though the 
majority of dogs succumb to disease rather quickly, considering the vast tumour-generated 
complications which can lead to death (triggering of catecholamine surges resulting in 
fulminant cardiac arrest, tumour thrombosis, rupture, and spread to local and distant sites), 
according to Reusch (2015), patients handled exclusively medically with phenoxybenzamine 
may still live for more than a year after the diagnosis. 
Interestingly, a case report documents the conservative management of a dog with a malignant 
phaeochromocytoma, by means of radiotherapy using iodine-131 metaiodobenzylguanidine 
(Bommarito et al., 2011). The treatment was clinically well tolerated with a notable 
improvement in clinical signs after the first session. To determine clinical utility of this 






2.2 Surgical management 
2.2.1 Indications 
In spite of being a technically challenging surgical procedure, commonly associated to intra- 
and postoperative complications resulting in high mortality rates, adrenalectomy is still widely 
recognised as the treatment of choice in dogs in the following circumstances: with functional 
adrenocortical tumours, phaeochromocytomas, large masses, and in presence of malignancy 
characteristics. Accordingly, in case of benign, small, non-invasive, and non-producing 
neoplasms, there might be no indication for surgery. Sadly, this assessment is quite difficult to 
predetermine without excision and histopathological examination. Even with non-functional 
tumours, there is still a risk for local and distant spread, thus, rendering virtually impossible to 
predict tumour evolution (Behrend, 2015; Myers, 1997; Reusch, 2015). 
Size may be a helpful feature in guiding the decision process. As previously mentioned, any 
mass measuring ≥ 20 mm in maximum diameter or presenting signs of vascular invasion, 
warrants suspicion of malignancy (Cook et al., 2014; Labelle et al., 2004) and growth potential 
(Arenas et al., 2013); thus, adrenalectomy ought to be recommended in these cases.  
Interestingly, occurrence of metastases and/or tumour thrombi may not constitute outright 
contraindications for adrenalectomy (Anderson et al., 2001; Frankot, Behrend, Sebestyen, & 
Powers, 2012; Reusch, 2015). While it is unknown whether surgery will or not extend survival 
in patients with metastases, resections of tumours and their respective thrombus have been 
described with subsequently successful outcomes (Barrera et al., 2013; Kyles et al., 2003; Lang 
et al., 2011; Reusch, 2015). 
 
2.2.2 Perioperative management 
In the preoperative period, ideally as close as possible of the surgical intervention, key tumour-
related features, that may alter the surgical plan or the expected risk for intra- or postoperative 
complications, should be reassessed. Thoracic radiography to rule out pulmonary metastases 
and abdominal ultrasonography to obtain an updated dimension of the mass, evaluate local 
invasion (specifically, vascular invasion and tumour thrombus characteristics), identify 
eventual haemorrhage within the tumour or retroperitoneal space, and also search for metastatic 
lesions on other abdominal structures (with or without US-FNA to attain confirmation) 
(Behrend, 2015). These imaging verifications can be superiorly fulfilled with CT or MRI 
(Armbrust et al., 2012; Goldfarb et al., 1990; Schultz et al., 2009). 
When vascular invasion is identified in pre-surgical evaluations, blood typing and cross-
matching should be part of preoperative measures in consideration of the risk of significant 
blood loss that might result from venotomy or tumour dissection (e.g., iatrogenic laceration of 
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the CVC or aorta) and consequent necessity of intraoperative blood transfusion (Barrera et al., 
2013; Behrend, 2015; Kyles et al., 2003; Oblak et al., 2016; Schwartz et al., 2008). Also, 
preparations can be made to systematically induce intraoperative hypothermia (oesophageal 
temperature of 32°C), before vascular occlusion, as a protective measure against tissue ischemia 
(Kyles et al., 2003). 
These procedures are advocated irrespectively of type of adrenal tumour. 
 
2.2.2.1 Adrenocortical tumours 
As a result of functional ATs, several worrisome complications may arise, namely, cortisol-
induced immunosuppression, compromised wound healing, systemic hypertension, 
hypercoagulability and consequent thromboembolism, local invasion (namely, major-caliber 
vessels), hypoadrenocorticism, and pancreatitis (Behrend, 2015). Therefore, perioperative 
medical therapy may be key in preventing or reducing many of these adversities. 
Short-term treatment targeting to reduce or reverse HAC and its respective metabolic 
consequences may be accomplished with trilostane for 3-4 weeks prior to surgery. The aim is 
to improve clinical presentation and reduce post-ACTH serum cortisol levels, so that 
adrenalectomy can be pursued as soon as hypercortisolemia is tamed. However, irrespectively 
of the state of control, surgery should not be booked for later than 30 days after beginning the 
medication. Serum electrolytes should be monitor at the same time for alterations consistent 
with hypoaldosteronism (Behrend, 2015; Vaughan, Feldman, Hoar, & Nelson, 2008). 
As a part of the preoperative assessment, BP should be measured and addressed fittingly, along 
with routine preanesthetic bloodwork and urinalysis. Even though it might be possible to 
normalise HAC-related hypertension once the HAC itself is under control, severely elevated 
systolic BP (> 180 mm Hg) may warrant initiation of antihypertensive therapy (Behrent, 2015). 
PTE is a major complication caused by HAC which can result in death and it is typically noted 
within the first 72h after surgery (Adin & Nelson, 2012; Behrend, 2015). Despite inexistence 
of a proven protective effect, anticoagulant therapy may still be routinely used to combat 
thromboembolic events (Barrera et al., 2013; Kyles et al., 2003). A protocol suggested by Adin 
& Nelson (2012) includes intraoperative intravenous administration of heparinised plasma to 
supply antithrombin III, to be continued postoperatively with subcutaneous heparin 
administration during 2-3 days at gradually reducing doses. In addition, adequate anesthetic 
and pain relief therapy to attain quick return to ambulatory condition (within 4h of surgery) 
works in favour of circulation and, consequently, minimizes clot formation. 
Recognition of PTE in the perioperative period may be tricky in consideration of highly 
variable, inconsistent, and nonspecific clinical signs, as a result of equally variable degrees of 
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physiological impairment. Dyspnoea, tachypnoea and depression are the most common signs; 
coughing, haemoptysis, cyanosis, syncope, collapse, and sudden death may also occur. Physical 
examination may reveal harsh respiratory sounds or crackles upon auscultation, as well as, 
tachycardia with a louder or split 2nd heart sound. Conversely, auscultation may be muffled 
(due to pleural effusion) and other indications of congestive right-sided heart failure (e.g. 
jugular pulse, ascites) or deficient forward heart function (pale mucous membranes, prolonged 
capillary refill time, weak pulse) may occur. Basic bloodwork abnormalities are of limited 
added value, routine coagulation profiles are typically normal, and blood gas analysis are 
nonspecific – results may contribute to escalate the suspicion (hypoxaemia, hypocapnia, raised 
alveolar-arterial gradient) or may be normal; thus, without power to confirm or exclude the 
diagnosis. Plain thoracic radiographs most commonly reveal an alveolar or alveolar interstitial 
pattern in one or multiple areas, though, selective pulmonary angiography is the appointed 
diagnostic gold standard (until CT angiography becomes promptly available).  However, most 
of these patients are unstable, representing a high anaesthetic risk, and therefore, this and other 
useful diagnostic tools (such as, CT and MRI) are rendered unviable. Ultimately, PTE is 
frequently a diagnosis of exclusion. Anticoagulant, and/or platelet antiaggregant medication 
should be instituted accordingly with individual patient necessity (Goggs et al., 2009).  
Acute hypoadrenocorticism is also expected after removal of an endocrinologically active AT. 
The return of this physiologic function is dependent on the degree of atrophy of the contralateral 
adrenal secreting-cells. To prevent hypoadrenocorticism, intravenous fluids should be used (at 
a surgical maintenance rate) and, after intraoperative excision of the tumour, dexamethasone 
can be administrated intravenously. Glucocorticoid supplementation prior to surgery is 
contraindicated on the basis that it might increase the risk of facing perioperative complications, 
specifically, hypertension, overhydration, and thromboembolism. In the postoperative period, 
dexamethasone should be continued at inferior doses (Anderson et al., 2001; Andrade et al., 
2014; Behrend, 2015; Kyles et al., 2003; Lang et al., 2011; Massari et al., 2011). Afterwards, 
upon full regain of autonomous eating and drinking, prednisone may start to be progressively 
reduced over an extended time period (up to 3-6 months) while keeping a close eye on appetite, 
lethargy, and vomiting. This process can be monitored with ACTHSTs: a normal test result 
renders glucocorticoid supplementation unnecessary; a low test result proves glucocorticoid 
insufficiency and the need to elevate the prednisone dosage if matching clinical signs are also 
reported during tapering. The ACTHST may also be used to evaluate surgery success and, at 
the same time, to assert the real necessity for glucocorticoid supportive therapy. This is, when 
performed 6-8h postoperatively, reduced pre-ACTH and post-ACTH serum cortisol 
concentrations support the successful complete removal of the neoplasm and the demand for 
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supportive drug therapy; yet, non-functional metastases cannot be ruled out. Conversely, if 
values obtained were similar to the previous preoperative results, it could be argued that 
functional tumour cells are still present and supplementation with glucocorticoids is uncalled-
for (Behrend, 2015). 
Besides postoperative hypocortisolism, hypoaldosteronism may also occur since aldosterone-
secreting cells can also suffer from a certain level of atrophy. Hence, development of 
hyponatremia and hyperkalaemia should be closely monitored, especially in the first 72h 
following surgery. Nevertheless, this electrolyte imbalance is commonly transient, lasting about 
24-48h and normalising once substitution glucocorticoid therapy is tapered and the animal 
resumes normal feeding routines. However, it is impossible to predict and distinguish the 
patients that will have a self-limiting electrolyte derangement from those who will seriously 
need mineralocorticoids supplementation. Therefore, and because short-term therapy is rather 
benign, it is advisable to start supplementation if the imbalance lasts longer than 72h or when 
serum sodium is < 135 mEq/L or serum potassium is > 6.5 mEq/L (Behrend, 2015). 
Mineralocorticoid substitution may be accomplished with injectable desoxycorticosterone 
pivalate (Lynn, Feldman, & Nelson, 1993); or oral fludrocortisone acetate to be reduced and 
eventually discontinued within 1-2 weeks. Measurement of serum electrolytes is used to guide 
the process and adopt accordingly dose adjustments (Behrend, 2015). 
When bilateral adrenalectomy is pursued (Anderson et al., 2001; Behrend, 2015; Kyles et al., 
2003; Lang et al., 2011; Oblak et al., 2016; van Sluijs et al., 1995), life-long substitution therapy 
with gluco- and/or mineralocorticoids will be required. 
 
2.2.2.2 Phaeochromocytomas 
Depending upon the exact perioperative moment, a different set of complications is expected 
to arise from the effects of excessive catecholamine release. While anaesthetic induction and 
surgical handling of the tumour may spike circulating catecholamine levels with subsequent 
severe events of hypertension, tachycardia, cardiac arrhythmias, and even cardiac arrest; after 
excision of the tumour, the inverse (hypotension) may occur due to a brisk drop of blood 
catecholamines resulting in equally rapid descent of vascular tone and resistance (Adin & 
Nelson, 2012; Herrera et al., 2008; Reusch, 2015). 
Neither hormonal nor anticoagulant treatments are indicated in the peri- or postoperative 
periods in dogs with phaeochromocytomas alone (Adin & Nelson, 2012). However, if the 
tumour origin is uncertain (cortical or medullar) or if there is a suspicion of a concurrent 
functional AT, the recommendation is to proceed with the administration of dexamethasone 
and evaluate the need for further supplementation in the postoperative period (Reusch, 2015). 
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In dogs with phaeochromocytomas, preoperative treatment with phenoxybenzamine (a non-
competitive -adrenergic receptor antagonist) can be useful. The intention is to reverse 
vasoconstriction and hypovolaemia prior to surgery, to control/stabilise fluctuations of BP, 
heart rate, and rhythm before and during anaesthesia, and ultimately, to influence surgical 
outcome (i.e., survival). In fact, Herrera et al. (2008) reported a significantly lower mortality 
rate in a group of dogs pre-treated with phenoxybenzamine (13%) in comparison to the 
untreated group (48%), with the former being 6 times more likely to survive surgery than the 
latter. However, the etiologic mechanism behind these results was unclear taking into account 
that no significant differences were found in regard to theoretically influencing factors: intra- 
and postoperative frequency and severity of hypertensive and hypotensive episodes, and intra- 
and postoperative BP variability. Moreover, in another study, phenoxybenzamine did not have 
a significant protective effect as previously reported (Barrera et al., 2013). Still, the results 
obtained by Herrera et al. (2008) do strongly support pre-adrenalectomy therapy with 
phenoxybenzamine in dogs with phaeochromocytomas; and its use has been frequently stated 
(Andrade et al., 2014; Barrera et al., 2013; Gilson, Withrow, & Orton, 1994; Kyles et al., 2003; 
Massari et al., 2011; Oblak et al., 2016; Schwartz et al., 2008). 
Currently, is still uncertain which dose and duration of drug therapy are the best effect-wise. 
The protocol used by Reusch (2015) involves the administration of phenoxybenzamine in 
progressively augmented doses up to a maximal dose or until the patient exhibits signs of 
hypotension (e.g., lethargy, weakness, syncope) or other adverse side effects (e.g., tachycardia, 
vomiting). Monitoring throughout the treatment period and dose adjustments are generally 
based on owner feedback, although regular examination of BP, heart rate, and heart rhythm 
would be preferable. The surgery may be planned for ~2 weeks after the start of 
phenoxybenzamine, with the last dose being given in the evening before the intervention. This 
protocol is standardly used in dogs undergoing adrenalectomy for their phaeochromocytomas, 
in spite of being hyper- or normotensive when examined. Additionally, if persistent tachycardia 
or tachyarrhythmias are recognised, preoperative therapy may be complemented with a β-
adrenergic receptor antagonist (preferably a selective β1-blocker – e.g., atenolol), but never 
before or soon after initiation of  -adrenergic blockade medication, in consideration of the risk 
of severe hypertension. 
Hospitalisation prior to adrenalectomy is recommended sooner rather than later (24h before), 
in order to assert and monitor BP, heart rate and rhythm, as well as, to regularise circulating 
volume through institution of fluid therapy (at maintenance rate). It is also imperative to 
maintain a close monitorisation of these parameters during the subsequent high-risk periods for 
the development of hypertension and arrhythmias (anaesthetic induction and surgery), as well 
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as, after the intervention (Adin & Nelson, 2012; Reusch, 2015). Various anaesthetic drugs can 
be used, although one might want to steer clear of those that are arrhythmogenic, 
anticholinergic, act on -receptors, or amplify the effects of catecholamines (Adin & Nelson, 
2012); thus, avoiding increasing the risk of complications. 
Taking into account the already described implications of manipulating the tumour, it is vital 
that the surgeon and the anaesthesiologist work in an intimate relationship. Whereas the former 
should give fair warning before carefully approaching the area of the tumour, the latter should 
be readily prepared drugs-wise to face inherent complications (Reusch, 2015). Persistent 
tachycardia and tachyarrhythmias can be handled with esmolol (an ultra-short-acting β1 
blocker) (Kyles et al., 2003; Lang et al., 2011), while lidocaine or procainamide are adequate 
for more serious ventricular arrhythmias (Lang et al., 2011; Whittemore et al., 2001). With 
regard to hypertension, management methods include deepening of the anaesthesia and/or 
administration of phentolamine (a short-acting α-adrenergic blocker) and/or nitroprusside (a 
direct vasodilator) (Kyles et al., 2003; Lang et al., 2011; Reusch, 2015). To deal with 
hypotension, other BP dropping treatments should be primarily reduced or interrupted, and 
thereafter, crystalloid (or colloid) fluids can be used to replace intravascular volume (Gilson, 
Withrow, & Orton, 1994; Kyles et al., 2003; Lang et al., 2011; Massari et al., 2011). In more 
serious cases, other drugs may be added to increase contractility (e.g., dobutamine) or vascular 
tone (e.g., phenylephrine, norepinephrine, vasopressin) (Gilson, Withrow, & Orton, 1994; 
Kyles et al., 2003; Reusch, 2015). Furthermore, an effort to keep surgical time to minimum 
might be crucial according to Herrera et al. (2008). In their study, for every hour increase in 
surgical time, the likelihood of 10-day survival dropped by 75%. 
After the procedure, equally thorough monitorisation should be continued for at least 48h, as 
episodes of arrhythmias, and BP derangements may still occur. Hypotension may be attributed 
to the resection of the tumour and consequential abrupt fall in blood catecholamines or may 
suggest haemorrhage. Accordingly, in theory, hypertension would not be expected and may 
indicate remnant functional neoplastic tissue (primary or metastatic) (Reusch, 2015). 
As anteriorly mentioned, bilateral adrenalectomy implicates subsequent gluco- and/or 
mineralocorticoid replacement for life. Fortunately, in the event of bilateral medullary tumours, 
there might be a chance of avoiding this setback if adrenal cortex-sparing surgery is attempted 
–  so far only reported in human medicine (Esen et al., 2012). Yet, interestingly, a unilateral 
complete followed by a contralateral partial adrenalectomies were reported in a canine patient, 
which permitted the maintenance of adequate adrenal function with no need of supplementation 
therapy (Larson et al., 2013). 
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2.2.3 Surgical approaches 
2.2.3.1 Ventral midline celiotomy with or without a paracostal extension 
A ventral midline celiotomy is the most frequently used approach to surgical manage the 
adrenal glands in dogs (Anderson et al., 2001; Gilson, Withrow, & Orton, 1994; Herrera et al., 
2008; Kyles et al., 2003; Massari et al., 2011; Oblak et al., 2016), probably because of 
familiarity with the technique and associated anatomic perspective. Besides, it is the only 
method to enable full abdominal exploration and bilateral procedures through a single wound, 
and may prevent postoperative discomfort associated with muscular transection by entering the 
abdomen through the linea alba instead. In case of large adherent masses and when temporary 
occlusion of circulation is required during resection, a ventral midline incision provides better 
exposure, namely, of the vessels like the CVC. On the other hand, accessing the dorsal 
retroperitoneal space may be difficult, especially, in large and deep-chested patients. Extending 
the cranial aspect of the midline incision into a paracostal one may prove helpful in these cases, 
though it is rarely needed (Adin & Nelson, 2012; Anderson et al., 2001; Fossum & Caplan, 
2013; Massari et al., 2011). In certain cases, visualisation may also be improved through 
mobilisation of the falciform ligament, either by releasing it from one or both sides of the 
incision, or by its excision after respective ligation at its base (Tillson & Tobias, 2012). To 
expose the left adrenal and kidney, the colon should be retracted medially; the right adrenal 
gland is more challenging, hence, the hepatorenal ligament can be broken/cut followed by 
cranial retraction of the right lateral and caudate liver lobes to simplify the task ahead. 
Regardless the side which will be addressed, self-retaining abdominal retractors (e.g. Balfour) 
should be placed primarily. Nonabsorbable monofilament suture material has been advised to 
close the linea alba in consideration of the delayed wound healing expected in patients with 
HAC (Adin & Nelson, 2012). Because the degree of this compromise is hard to judge, stitches 
should stay put until regrowth of hair in the area of the incision is perceived, irrespectively of 
the surgical approach used (Behrend, 2015). When a paracostal extension is made, closure 
should start by approaching the abdominal wall at the connection point between both incisions, 
followed by closure of the linea alba, and lastly, closure of the paracostal wound (each muscle 
layer individually) (Fossum & Caplan, 2013). 
 
2.2.3.2 Flank/Paracostal/Paralumbar/Retroperitoneal approach 
Referred by different nominations, this approach is less invasive/traumatic, provides better 
access to the dorsal abdomen (especially in right-sided adrenalectomies), and the risk of 
pancreatic injury and wound breaking with subsequent herniation is considerably inferior in 
comparison to the midline celiotomy. Nonetheless, it is only appropriated for unilateral 
procedures and more straightforward tumour resections. Hence, proper presurgical abdominal 
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imaging should take place to ensure no other structures need handling or further exploration 
(Adin & Nelson, 2012; Emms, Wortman, Johnston, & Goldschmidt, 1986; Fossum & Caplan, 
2013; van Sluijs et al., 1995). 
The animal is positioned in lateral recumbency and an elevating object may be placed (e.g. 
rolled towel or sandbag) between the abdomen and the surgical table. The skin incision is made 
just caudally to the last rib, with roughly 10-14 cm in length, starting from the lateral vertebral 
processes and finishing 3-4 cm before the ventral midline (Fossum & Caplan, 2013). Thereafter, 
the muscles layers are incised separately and following each respective fibber orientation. To 
expose the adrenal gland, the ipsilateral kidney should be retracted ventrally with care 
throughout in order to avoid traumatising and consequent rupturing of near-by vascular 
structures. If required, the last ribs may be sectioned and retracted cranially. In patients with 
HAC, it is still advisable to use nonabsorbable monofilament suture material when closing the 
muscle wall layers individually, despite the unlikelihood of wound breaking down occurring in 
comparison to an approach through the linea alba (Adin & Nelson, 2012).  
More recently, a 12th intercostal space approach for right adrenalectomy specifically, with or 
without involvement of the CVC, has been described by Andrade et al. (2014) as a superior 
method of exposure of the right adrenal and associated vasculature in detriment of the 
paracostal, midline or a combination of both approaches. Obtaining suitable access is a 
persistent challenge common to the paracostal and midline approaches because of the 
positioning of the right adrenal gland: far cranial, under the ribs, dorsal to the CVC. Excellent 
access with acceptable complication rates and clinical outcomes were reported with this 
innovative intercostal approach (Andrade et al., 2014). 
 
2.2.3.3 Laparoscopy approach 
Laparoscopic adrenalectomy (LA) combines the best of both previously described techniques 
by permitting a thorough abdominal exploration while being a minimal invasive procedure with 
enhanced visualisation and exposure (Adin & Nelson, 2012; Jiménez-Peláez et al., 2008; 
Mayhew, 2009). In comparison to open procedures, LA studies have described faster 
recoveries, shorter hospitalisation periods, fewer and only minor wound complications, and 
shorter operative times (Jiménez-Peláez et al., 2008; Mayhew et al., 2014; Naan, Kirpensteijn, 
Dupré, Galac, & Radlinsky, 2013; Pitt et al., 2016). Moreover, dogs with known cortisol-
secreting ATs submitted to LA might benefit from a superior prevention of thromboembolism 
considering that they will recover to ambulatory condition faster, thus enabling frequent short 
walks and, ultimately, promoting blood flow and minimizing clot formation (Behrend, 2015). 
Additionally, the use of LA might be of particular interest in the event of incidentally found 
adrenal masses of uncertain clinical significance (Ko et al., 2018; Mayhew, 2009). Indeed, 
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because surgical removal and histopathological examination are the only way to attain a definite 
diagnosis and prognosis, the minimal traumatic nature of this method works in favour of opting 
for surgery sooner rather than later. 
Careful patient selection is imperative. LA is conditioned by large masses (> 6 cm) or vascular 
invasion, for which open adrenalectomy is indicated; thus, the importance of preoperative 
diagnostic imaging. Other contraindications include animals with systemic instability, 
uncontrolled metabolic or acid-base disturbances and coagulopathies, untreated severe 
arrhythmias, hypertension, and conditions that determine poor tolerance to pneumoperitoneum 
(e.g., severe cardiorespiratory disease, diaphragmatic herniation) (Mayhew, 2009). 
An important downside of LA is the compromised ability to tackle intraoperative complications 
such as haemorrhage. Occasionally, if significant haemorrhage occurs, the procedure has to be 
immediately converted to an open approach (Mayhew et al., 2014; Pitt et al., 2016). 
Furthermore, despite its clinical consequences remaining unclear, capsule disruption and 
masses removed in fragments might raise concern for abdominal tumour seeding and should be 
avoid as much as possible (Jiménez-Peláez et al., 2008; Mayhew, 2009; Mayhew et al., 2014; 
Naan et al., 2013). 
Very recently, a pilot study evaluated the feasibility of a new modality of LA in dogs with an 
interesting promise of providing better outcomes with minimal complications, postoperative 
pain, or damage to the adrenal gland – single-port retroperitoneoscopic adrenalectomy (SPRA) 
(Ko et al., 2018). In detriment of other transabdominal LA techniques, SPRA provided direct 
access to and a clear view of the adrenal gland without necessity of retracting other organs. 
Anticipated advantages include: shorter operative time, less blood loss, less pain, better patient 
comfort, faster recovery, superior cosmetic results, reduced risk of postoperative adhesions and 
of tumor cells seeding to the abdominal organs. On the other hand, the small working space 
may prove challenging to work with, the ability to explore other organs is rather compromised, 
and tumour size might limit applicability of this technique to benign tumours (e.g., adenomas) 
and small incidentalomas, up to 3 cm (based on the 3 cm incision used in the study). 
 
2.2.4 Surgical technique 
Irrespective of the chosen surgical approach, obtaining a perfectly adequate exposure is an 
adversity shared by all techniques, thus having a surgical assistance may be vital to achieve 
suitable retraction. Dissection of the gland is often started at the lateral aspect, distantly from 
the large calibre vasculature, with ligation and transection of the formerly-denominated 
phrenicoabdominal vein at the lateral border of the gland. This free-end is manipulated 
medially, aided by a stay suture or an atraumatic instrument, revealing dorsal vascular branches 
to be addressed. Thereafter, dissection progresses on the caudal border of the gland, with 
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occlusion of renal arterial branches. At this stage, if the kidney or its correspondent irrigation 
appears to have been invaded, concurrent ipsilateral nephrectomy may be warranted. Finally, 
prior to complete tumour excision, the medial plane is bluntly dissected and the common trunk 
(for the caudal phrenic and cranial abdominal veins) has to be ligated close to its entry point on 
the CVC (Adin & Nelson, 2012). Due to the intimate relation between the CVC and the right 
adrenal capsule (Hullinger, 2013), the utmost care while separating the two structures is vital 
to prevent iatrogenic rupture of the venae cava (Adin & Nelson, 2012; Oblak et al., 2016). 
Availability of vascular clips, mono- or bipolar electrocoagulation, or a vessel-sealing device 
can ease haemostasis throughout the dissection process (Andrade et al., 2014; Jiménez-Peláez 
et al., 2008; Ko et al., 2018; Lang et al., 2011; Massari et al., 2011; Mayhew et al., 2014; Naan 
et al., 2013; Oblak et al., 2016; Pitt et al., 2016).  
 
2.2.4.1 CVC Venotomy and Thrombectomy 
Caval thrombi has been reported to occur in 33 to 55% of dogs with phaeochromocytomas 
(Barrera et al., 2013; Bouayad et al., 1987; Kyles et al., 2003; Lang et al., 2011; Twedt & 
Wheeler, 1984) and as high as 71% (Herrera et al., 2008). Lower rates of caval thrombi, from 
2 to 21%, have been reported in dogs with ATs (Anderson et al., 2001; Barrera et al., 2013; 
Kyles et al., 2003; Lang et al., 2011; Scavelli et al., 1986). While this difference was found 
significant in two studies (Barrera et al., 2013; Kyles et al., 2003), no significant difference was 
found between right- and left-sided adrenal tumours invading the CVC in those same reports, 
though it seemed more common with right- (35%) than with left-sided (20%) neoplasms (Kyles 
et al., 2003).  
When addressing CVC invasion, Rumel tourniquets should be loosely applied primarily, even 
before any attempt of dissecting the neoplastic adrenal. They are positioned just caudal to the 
liver and just cranial to the renal veins; if the caudal tourniquet is placed caudally to the right 
renal vein, a third tourniquet is required around the referred vessel; if the thrombus extends into 
the intrahepatic CVC, the cranial tourniquet is tightened only after thrombectomy (Adin & 
Nelson, 2012; Fossum & Caplan, 2013; Kyles et al., 2003). Afterwards, the adrenal may be 
freed from its surrounding connections, leaving for last the entry point of the tumour thrombus 
in the CVC – right adjacently is the target area to perform a longitudinal incision in the vessel, 
but not before tightening the tourniquets (Figure 1). A suction device may help conserve a clear 
view by preventing blood pooling. Following thrombus excision, a minor quantity of blood 
may be permitted into the delimitated area (to prevent air embolism), the venotomy is isolated 
with a partial occlusion clamp and the tourniquets released. Either 4-0 or 5-0 suture material 
are appropriated to close the venotomy in a continuous pattern (Adin & Nelson, 2012).  
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Figure 1. Resection of a right-sided adrenal gland tumour invading the CVC (From: Adin, C. 
A., & Nelson, R.W. (2012). Adrenal Glands. In K. M., Tobias & S. A., Johnston (Eds.): 
Veterinary surgery: Small animal, (volume two), (p. 2041). Missouri: Saunders, Elsevier.). 
 
Caption: (A) Rumel tourniquets are applied to provide adequate temporary blood-flow 
occlusion of the CVC to allow tumour thrombus resection. (B) Blood-flow is restored 
while suturing the venotomy incision aided by a partial occlusion clamp. 
 
Blood-flow occlusion should be attempted to last as briefly as possible. MacPail (2013), in 
respect of inflow occlusion – a technique which entails interruption of all venous flow to the 
heart –, stipulates an ideal time between 2 and 4 minutes for circulatory arrest in normothermic 
animals. This period can be prolonged up to 8 minutes provided mild, whole-body induced-
hypothermia is attained to protect tissues from ischemia. To do so, oesophageal temperatures 
have to be maintain below 34C, yet, above 32C to prevent spontaneous ventricular fibrillation 
(Herrera et al., 2008; Kyles et al., 2003; MacPhail, 2013; Moon & Ilkiw, 1993). 
An experimental study has demonstrated that acute complete CVC occlusion can be safely 
performed in dogs for periods up to 8 minutes, with subsequent full haemodynamic recovery 
within 5 minutes (Hunt, Malik, Bellenger, & Pearson, 1992). The explanation behind was 
hypothesised by Horvath & Bender (1961), who argued that collateral circulation developed 
rapidly thus preventing major physiologic consequences. Likewise, another experimental study 
has shown the formation and growth of collateral vessels in cases of chronic gradual CVC 
occlusion (Peacock, Fossum, Bahr, Miller, & Edwards, 2003). 
A recent case report confirms previous published findings by supporting the ability of canine 
patients to survive prolonged acute CVC occlusions (Halwagi, Crawford, Hoddinott, & Oblak, 
2017). It describes a successful outcome with minimal postoperative complications (namely, 
mild pelvic limb oedema) following an 18-minute-long complete obstruction of the CVC, 
which resulted from iatrogenic transection and consequent repair of the CVC during right liver 
lobectomy to remove a hepatocellular carcinoma. In a follow-up CT scan 9 months later, 
extensive venous collateral neovascularisation and caval stricture were identified without any 
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associated clinical consequences. The dog remained alive and asymptomatic for more than 1 
year after surgery. 
Occasionally, due to extensive local invasiveness, tumour thrombi are deemed unresectable 
through venotomy. In such situations, segmental resections of the afflicted portion of the CVC 
(venectomies) have been described in two case reports of dogs with phaeochromocytomas: the 
suprarenal, infrahepatic CVC was excised en bloc with (Louvet, Lazard, & Denis, 2005) or 
without (Guillaumot et al., 2012) concurrent ipsilateral nephrectomy. In both cases, dogs were 
successfully managed and presented good long-term outcomes. This might be explained by the 
previously discussed logic, i.e., collateral circulation forms in simultaneous with the 
development of the tumour thrombus. Having this option might simplify the surgery itself and 
would also allow wider margins for tumour excision. 
 
3. OUTCOME FOLLOWING ADRENALECTOMY 
3.1 Complications 
A series of complications can be expected to derive from the hypercortisolism caused by an 
AT, specifically, because of concomitant immunosuppression, compromised wound healing, 
systemic hypertension, existence of a hypercoagulative state, and atrophy of the contralateral 
gland (Behrend, 2015). In dogs with phaeochromocytomas, complications are generally linked 
to the peaks and drops in catecholamine release, producing variations in blood pressure, hyper- 
and hypotensive episodes, and cardiac arrhythmias with potential to lead to cardiac arrest 
(Herrera et al., 2008). Additionally, the chosen surgical approach may also influence the 
existence of complications as poor exposure raises concern for intraoperative adversities such 
as the surgeon’s ability to prevent or address haemorrhage, as well as, iatrogenic injuries to the 
liver, pancreas, vena cava, and kidney (van Sluijs et al., 1995). 
When adrenal tumours in general are surgical managed, intraoperative complications are 
common and have been reported at different rates: 15% (Kyles et al., 2003), 43% (Lang et al., 
2011), 83% (Barrera et al., 2013). Main complications include haemorrhage, hypotension, 
hypertension, cardiac arrhythmias, which can result in death (Barrera et al., 2013; Kyles et al., 
2003; Lang et al., 2011; Schwartz et al., 2008). Acute haemorrhage may be secondary to a 
ruptured adrenal tumour (Lang et al., 2011; Whittemore et al., 2001) or to inadvertent injury of 
abdominal viscera and vascular structures while dissecting or struggling for adequate exposure 
(Kyles et al., 2003; van Sluijs et al., 1995). 
Likewise, postoperative complications are reported at high rates, ranging from 30 to 51%, and 
include hypotension, pancreatitis, renal insufficiency/failure, peritonitis, PTE, cardiac 
arrhythmias, cardiac arrest, disseminated intravascular coagulopathy (DIC), 
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hypoadrenocorticism, wound dehiscence, haemoperitoneum, vomiting, diarrhoea, tachypnoea, 
dyspnoea, and hypoxaemia (Barrera et al., 2013; Kyles et al., 2003; Lang et al., 2011; Schwartz 
et al., 2008). Furthermore, it is not uncommon for dogs to develop more than one of these 
complications (5/13, 38%) (Schwartz et al., 2008). Also, postoperative complications were 
found to occur with no significant different between dogs with ATs and those with 
phaeochromocytomas (Barrera et al., 2013; Kyles et al., 2003). 
 
3.2 Mortality 
In earlier case series, overall mortality rates of dogs undergoing surgical excision of an AT 
were reported to be as high as 28% (10/36) (van Sluijs et al., 1995) and 60% (15/25) (Scavelli 
et al., 1986). Dogs were euthanised at time of surgery for a variety of reasons (e.g., deemed 
unresectable masses, visible metastases, vascular invasion) or died from serious complications 
in the postoperative period (up to 2 weeks). Similarly, high rates have been reported in dogs 
with phaeochromocytomas: 33% (2/6) (Gilson, Withrow, & Orton, 1994) and 47% (8/17) 
(Barthez et al., 1997). What is more, in the study by Barthez et al. (1997) 29% (5/17) of dogs 
died from cardiac arrest or were euthanised (because of widespread metastatic disease or a 
tumour judged unresectable) during the surgical intervention. 
Interestingly, subsequent reports have demonstrated an improvement in the overall 
perioperative mortality rates for dogs with adrenal tumours in general:  22% (9/40) (Kyles et 
al., 2003), 22% (9/41) (Schwartz et al., 2008), 15% (8/52) (Massari et al., 2011), 12% (7/60) 
(Lang et al, 2011), 26% (22/86) (Barrera et al., 2013). Possible explanations include improved 
case selection as a result of increased availability of advance imaging methods, precluding 
surgery in patients with irremediable disease (e.g., already spread to distant sites, irresectable 
masses) (Armbrust et al., 2012; Schultz et al., 2009); altered preconceptions regarding the 
impact of caval thrombi on perioperative morbidity and mortality rates, which have been shown 
not to suffer significant increases provided that the surgeon is familiarised with appropriate 
techniques (Kyles et al., 2003) and the tumour thrombus does not extend into or beyond the 
hepatic portion of the CVC (Barrera et al., 2013); and also, the developments in perioperative 
management and anaesthetic techniques might have positively influenced outcomes – a theory 
supported by the results of Herrera et al. (2008), where mortality associated with adrenalectomy 
was observed to be significantly decreased (from 48% to 13%) by using phenoxybenzamine 
preoperatively. 
Yet, for those dogs undergoing emergency adrenalectomy due to acute adrenal haemorrhage 
(AAH), mortality rates might be higher. In their study, Lang et al. (2011) observed that 4 of 8 
dogs (50%) died in the perioperative period as result of euthanasia (suspected PTE, refractory 
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seizures, progressive lung oedema) or cardiopulmonary arrest, surviving between 1 to 4 days. 
In another case series involving 4 dogs with AAH, for 1 dog (25%) euthanasia was elected 
during surgery due to failure to accomplish resection and attain adequate haemostasis 
(Whittemore et al., 2001). 
In regard of bilateral procedures, a recent case series reported the outcome of bilateral 
adrenalectomy in 9 dogs (7 concurrent, 2 staged) with a perioperative mortality of 11% – a rate  
comparable to those of elective unilateral adrenalectomies (Oblak et al., 2016). 
 
3.3 Survival 
Reported median survival times (MST) for dogs undergoing adrenalectomy for adrenocortical 
carcinomas was 778 days or, if those who did not survive the immediate 14 days post-surgery 
were to be excluded, MST would be 992 days with long-term survival extending up to 1593 
days (Anderson et al., 2001). Other studies reported MST of 48 months, 360 days, and 230 days 
for dogs with carcinomas (Barrera et al., 2013; Massari et al., 2011; Schwartz et al., 2008), 
compared to 688 for dogs with adenomas (Schwartz et al., 2008). 
In regard of phaeochromocytomas, Schwartz et al. (2008) reported a MST of 374 days, and 
some dogs may survive for as long as 2 to 3 years (Barthez et al., 1997; Gilson, Withrow, & 
Orton, 1994). 
What is more, Barrera et al. (2013) observed 1-, 2-, and 3-year survival rates of 88% for 
adrenocortical carcinomas, and 83%, 60%, and 60%, respectively, for phaeochromocytomas. 
When all adrenal gland tumours are considered, overall MST reported has varied from 375 to 
953 days (Lang et al., 2011; Massari et al., 2011; Schwartz et al., 2008), and in one study 65% 
survived more than 1 year, up to 1941 days (~5 years) (Massari et al., 2011). 
Even for those patients presented as surgical emergencies with AAH, to whom a high mortality 
rate (50%) is associated, MST was 208 days (overall) and 844 days for the 4 dogs that survived 
the designated perioperative period which had extended survival times of up to 1020 days, and 
none was reported to have died or been euthanised due to recurrence of clinical signs or 
metastases (Lang et al., 2011). 
Moreover, interesting case reports describe notably extended long-term survival times allied to 
somewhat unexpected circumstances: the resection of phaeochromocytomas, which also 
implicated an en bloc excision of a suprarenal part of the CVC, as the concomitant tumour 
thrombi were deemed unresectable through venotomy. While one dog was clinical well, with 
no significant vascular or renal dysfunction, at a follow-up 20 months after surgery (Louvet et 
al., 2005), another survived for 49 months postoperatively and was healthy until then – it died 
of unknown causes after a hyperacute onset of vomiting and diarrhoea (Guillaumot et al., 2012). 
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3.4 Prognosis 
A number of investigators have evaluated prognostic factors, namely predictors for short-term 
survival, for dogs with different types of adrenal gland neoplasms undergoing adrenalectomy. 
Preoperative variables significantly associated with shorter survival times included adrenal 
gland tumour size (particularly, when the major axis length was ≥ 5cm), vein thrombosis, 
extensive invasion of the CVC (into or beyond the hepatic hilus), weakness, lethargy, increased 
blood urea nitrogen concentration, thrombocytopenia, increased partial thromboplastin time, 
increased aspartate transaminase, hypokalaemia, presence of metastases, and presence of AAH 
(Barrera et al., 2013; Lang et al., 2011; Massari et al., 2011; Schwartz et al., 2008). 
Intraoperative variables significantly associated with shorter survival times included blood loss 
requiring transfusion, and concurrent nephrectomy (Barrera et al., 2013; Schwartz et al., 2008). 
Postoperative variables significantly associated with shorter survival times were development 
of pancreatitis, acute renal failure, DIC, hypotension, and hypoxemia (for which PTE is a 
possible cause, although it could not be confirmed due to the retrospective nature of the studies) 
(Barrera et al., 2013; Schwartz et al., 2008). 
These results, however, should be interpreted critically in terms of their clinical relevance as 
some of these findings lacked in specificity and/or were found in a small number of patients 
(Schwartz et al., 2008). Besides, reports can be conflictive about which factors are in fact of 
prognostic significance or not. 
To start with, the presence of tumor thrombus was not predictive of outcome, with no significant 
differences in perioperative morbidity and mortality, or in survival duration in several studies 
(Herrera et al., 2008; Kyles et al., 2003; Lang et al., 2011; Schwartz et al., 2008). Conversely, 
Massari et al. (2011) found that vein thrombosis was associated with a poorer prognosis and 
also with “larger” neoplasms (major axis length ≥ 5cm). In a more recent study (Barrera et al., 
2013), both invasion of the CVC and extent of the tumour thrombus were risk factors for death 
in the short-term. Yet, when invasion of the CVC was adjusted for the extent of the tumor, 
invasion of the CVC was no longer a risk factor, which is in agreement with the results of Kyles 
et al. (2003). Thus, it appeared that extensive caval invasion was the most important risk factor 
for poor short-term survival. Still, long-term survival was possible regardless of invasion status 
or any other risk factor evaluated for that matter. 
Secondly, the histological type of tumour was also not related with survival time in various case 
series (Anderson et al., 2001; Kyles et al., 2003; Lang et al., 2011; Schwartz et al., 2008). 
However, while in univariate analysis models, adrenocortical carcinomas (Massari et al., 2011) 
or phaeochromocytomas (Barrera et al., 2013) were significantly associated with a worse 
prognosis in detriment of other tumour types, they were not predictive of outcome in their 
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respective multivariate analysis. This is likely explained by the suggestive results of carcinomas 
being more likely to yield metastases, namely based on the highest rates of metastatic lesions 
registered for carcinomas in one study (Schwartz et al., 2008) and the significant association 
between the presence of metastases with carcinomas found by another (Massari et al., 2011). 
Similarly, the fact that caval invasion has been shown to occur at higher rates with 
phaeochromocytomas (Barrera et al., 2013; Bouayad et al., 1987; Herrera et al., 2008; Kyles et 
al., 2003; Lang et al., 2011; Twedt & Wheeler, 1984) and the high proportion (7/14) of 
extensively invasive CVC tumours found in the population studied by Barrera et al. (2013), 
clarifies the obtained results. Therefore, although the tumour type on its own is not predictive 
of outcome, its potentialities identified as negative prognostic factors make it a possible indirect 
risk factor to consider. 
Size-wise, while this variable was not associated with survival in some studies (Anderson et 
al., 2001; Herrera et al., 2008; Schwartz et al., 2008), it is possible that this finding was due to 
the great majority of tumours being relatively small, with a major axis length < 5 cm. In fact, 
Massari et al. (2011) observed that an adrenal gland tumour with major axis length ≥ 5 cm was 
associated with 85% shorter survival time. Moreover, Lang et al. (2011) found that each 1 mm 
increase in tumour size was associated with a 7.9% increase in odds of perioperative mortality 
and with a 6% increase in odds of AAH. From a subjective point of view, Lang et al. (2011) 
suggested that, because “smaller” tumours apparently had less local invasion, less 
intraoperative blood loss, shorter anaesthetic and operative periods, and fewer postoperative 
complications; early detection and surgical intervention might be associated with greater 
postoperative survival. 
In regard of detection of metastases at time of surgery, their prognostic implications are 
somewhat uncertain, with some reporting it as predictive for shorter survival (Massari et al., 
2011), whereas others discovered no significant differences in survival (Kyles et al., 2003; 
Schwartz et al., 2008). Furthermore, Schwartz et al. (2008) detected a high number of gross 
lesions in other organs during surgery; yet, the histologic evidence of metastases was low. 
Hence, euthanasia should not be advised exclusively on the basis of gross lesions identified 
during surgery. Likewise, it remains to be determined if partial tumour resection would provide 
a therapeutic benefit in comparison to no surgery at all. In one study, completeness of tumour 
excision was not prognostic for survival time (Schwartz et al. 2008). Reported successful 
outcomes in cases of residual disease at surgery include: 1 was alive at 18 months after resection 
with violation of tumour margins (Gilson, Withrow, & Orton, 1994); 1 had recurrence of 
clinical signs after 5 months since partial resection which resolved with medical treatment until 
being euthanised at 13 months after surgery (van Sluijs et al., 1995); 1 was alive after ~1 year 
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and 1 died of disease ~3 years later, after partial resections (Anderson et al., 2001); 1 was still 
alive and healthy at 9 months after emergency partial excision (Whittemore et al., 2001); 1 had 
recurrence of clinical signs after 2 years since incomplete surgical excision – hepatic metastases 
were detected at that point and were treated with lobectomies – and was reported doing well 
and clinically stable at ~3.5 years after initial presentation (Frankot et al., 2012). 
Even the survivors of emergency adrenalectomy due to AAH, might not be at increased risk for 
local or distant recurrence, as none were reported to have died or been euthanised due to relapse 
of clinical signs or metastatic disease (Lang et al., 2011). 
Therefore, incomplete excision of primary tumours, evidence of metastases, or ruptured adrenal 
tumours may not necessarily be indications for euthanasia. Still, it is assumed that there is a 
high probability for these dogs to eventually have relapses (Kyles et al., 2003). 
Finally, whereas age was not considered to significantly affect survival in dogs with ATs 
(Anderson et al., 2001) or adrenal tumours in general (Massari et al., 2011; Schwartz et al., 
2008), one study in dogs with phaeochromocytomas found that younger age was a significant 
prognostic factor for improved survival, as well as, preoperative medical treatment with 
phenoxybenzamine, lack of intraoperative arrhythmias, and decreased surgical time (Herrera et 
al., 2008).  
The bottom line is that there might be risk factors which are more significant than others, and 
indirect risks still have to be taken into consideration when pondering on prognosis. Uncertainty 
or contradictions regarding some variables identified as predictors of outcome dictate that, 
ultimately, clinical sense and experience prevails. In general, dogs with “large” tumours, 
infiltrated kidney or body wall, extensive CVC invasion, metastatic lesions, low anti-thrombin 
III concentrations, who are old, debilitated, or have serious endocrine manifestations 
originating from the tumour or concurrent concerning illnesses, are at high risk of developing 
serious perioperative complications and of having a poor outcome. A good prognosis benefits 
from earlier detection and intervention, an experienced surgeon-anesthesiologist team, and in-
depth understanding of adrenal gland physiology and perioperative care (Behrend, 2015; Lunn 
& Page, 2013; Reusch,2015). 
Overall, it has been consistently observed that if dogs survive the immediate perioperative 
period, long-term outcome is generally good with possibility of prolonged survival times, as 
local or distant tumour recurrence appears to be low. Adrenalectomy offers at least as good a 
prognosis as chronic medical management (Anderson et al., 2001; Barrera et al., 2013; Barthez 
et al., 1997; Gilson, Withrow, & Orton, 1994; Kyles et al., 2003; Lang et al., 2011; Massari et 





The purposes of this study were to describe the clinical features, surgical management and 








III. MATERIAL AND METHODS 
 
1. Case selection criteria 
Medical records of 16 dogs that underwent surgical management of adrenal gland lesions, at 
Kingston Veterinary Group (KVG, Hull, United Kingdom) and the Veterinary Teaching 
Hospital of the Faculty of Veterinary Medicine of the University of Lisbon (HEV, FMV-UL, 
Portugal), between the year of 2008 and June 2018, were reviewed. Inclusion criteria were dogs 
where adrenalectomy was performed. 
 
2. Medical records review 
Data was collected after review of medical records and occasionally through interview with 
owners and/or veterinarians involved with the cases. Clinical variables included: signalment, 
relevant history, clinical signs, physical examination findings, results of functional testing, 
imaging exams (radiography, US, CT), abdominocentesis, and US-FNA, pre- and postoperative 
drug therapy, surgical findings and procedures, intra- and postoperative complications, duration 
of hospitalisation, histopathology and necropsy examinations, follow-up, and outcome. 
 
3. Procedures 
3.1 Imaging assessment 
Evaluation of the suspected adrenal tumours, in terms of size, shape, appearance, and 
relationship with immediate structures (i.e., compression or invasion) was executed beforehand 
for every electice unilateral adrenalectomy. 
Presence of tumour thrombi, namely in the CVC, was systematically verified. This assessment 
was made either through US or abdominal CT (Figures 2 and 3). Both of these methods were 
also utilised in the inspection of distant spread in the abdominal cavity. For verification of 
pulmonary metastases, the preferred methods were thoracic radiography or CT. 
Regarding the clinical cases presented as emergencies, US and abdominal radiography assisted 
exclusively the diagnosis of abdominal effusion; comprehensive US scans were not pursued in 





Figure 2. Ultrasonographic pictures demonstrating the measurement of an adrenocortical 
myelolipoma (A) and verification of vascular invasion using Doppler (B) (Kindly dispensed by 
Dr. David Robinson, KVG). 
 
Figure 3. Computed-tomography pictures after administration of intravenous contrast 
representing a left-sided adrenocortical adenoma with a concurrent caval “true” thrombus 











Caption: (A) Arrow=filling-defect in CVC, suspected of being caused by a thrombus. 
(B) Left arrow= filling-defect in the CVC; Right arrow=altered left adrenal gland. 
 
3.2 Perioperative management 
Dogs suspected of having endocrinologically active ATs, based on clinical manifestations, 
basic bloodwork and results of functional tests (ACTHST, LDDST, UCCR), were treated with 
injectable dexamethasone postoperatively, which was continued with oral prednisolone in the 
postoperative period according to need. Mineralocorticoid supplementation (e.g., oral 
fludrocortisone or injectable desoxycorticosterone pivalate) was performed after surgery, when 




administrated postoperatively according to the suspicion of HAC and practitioner criteria, as a 
preventive measure of PTE. Furthermore, dogs would stay hospitalised for at least 24h after 
surgery to monitor for signs of PTE, among other aspects. 
Diagnostic work-up of phaeochromocytomas included measurement of blood pressure and 
functional testing. Because the plasma assay was performed by laboratories of human medicine, 
i.e., without species-specific reference ranges, the results were interpreted through comparison 
with the findings of relevant studies on the subject (Gostelow et al., 2013; Salesov et al., 2015). 
Those suspected of having phaeochromocytomas were preoperatively treated with 
phenoxybenzamine. 
 
3.3 Surgical technique 
The surgical intervention was performed in 11 dogs at KVG by 3 different veterinary surgeons 
and in 5 dogs at HEV by 4 different veterinary surgeons. Anaesthetic time was defined as the 
time period between induction and extubation. Surgical time was defined as the time period 
between skin incision and skin closure. 
A ventral midline approach was used in all dogs. When deemed appropriate, the falciform 
ligament was excised and one or two abdominal retractors were placed in in order to improve 
access. An exploration of the abdomen viscera in search of suspected metastatic alterations was 
performed systematically. Conversely, biopsies (e.g., of the liver) were not obtained in all cases. 
A surgical assistant helped with retraction of the abdominal viscera to enable approach of the 
adrenal gland. Local vasculature (CVC, aorta, renal artery and vein) was examined to identify 
vascular invasion and thrombi. The ipsilateral kidneys were also inspected for invasion and 
nephrectomy was executed if reckoned necessary. 
Regarding the 3 cases of haemoabdomen of unknown origin, firstly, the source of haemorrhage 
was procured and dealt with, prior to any attempt of dissection of the tumours. 
A combination of blunt and sharp dissection along with ligation and transection of relevant 
vessels (generally leaving the medial plane, including the phrenicoabdominal trunk, for last) 
were used to free the altered adrenals from their surrounding connections, before completing 
resection. 
In one case, tumoural invasion of the aorta wall without concurrent thrombus determined its 
partial resection and subsequent reconstruction. In another, the presence of a “true” thrombus 
in the CVC without any other signs of neoplastic invasion from the concurrent adrenal tumour, 
a 10 to 20-mm longitudinal incision in the vessel, posteriorly sutured in a continuous pattern, 
was sufficient to perform thrombectomy (Figure 4). In both scenarios, Rumel tourniquets were 
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placed primarily to occlude local circulation temporarily (aiming to last less than 4 minutes) in 
order to enable surgical handling of the vascular structures. 
Prior to closure, lavage of abdominal cavity was executed with a warmed saline solution and 
occasionally a splash of bupivacaine was applied into the surgical field. Routine layered wound 
closure was performed. The excised tissue was submitted to histopathological examination 
(Figure 5). 
 
Figure 4. Intraoperative view after removal of a “true” CVC thrombus in a patient with a left-
sided adrenocortical adenoma (Original photography). 
 
Caption: Arrow=sutured venotomy; Asterisk=adrenal tumour. Note 
the use of two sets of retractors to improve access and visualisation. 
 
Figure 5. Intraoperative view of the surgical field after removal of a right-sided adrenal gland 











Caption: Arrow=right renal vein; Asterisk=surgical field after removal 










All complications that occurred intra- and postoperatively were recorded, as well as, 
hospitalisation times, the need for substitution therapy, and palliative treatments pursued. Major 
and minor haemorrhage was defined according to the necessity or not of a transfusion, 
respectively. Cardiac arrhythmias were identified on the basis of electrocardiography. 
Bradycardia and tachycardia were defined as a heart rate < 60 and > 140 beats/min, respectively. 
Hypotension and hypertension were defined as systolic blood pressure < 80 and > 180 mm Hg, 
respectively. A diagnosis of pancreatitis was mainly based on clinical signs and response to 
symptomatic treatment and occasionally supported by US and specific pancreatic lipase assay. 
Hypoadrenocorticism was diagnosed on basis of clinical signs and measurement of electrolytes. 
Dogs were followed until death or, if still alive, until the most recent contact before the end of 
the study. Those lost to follow up were duly noted. Cause of death was classified as adrenal-
tumour related (directly, or indirectly from consequences of the intervention) or non-related. 
This distinction was mainly based on clinical signs, physical examination, laboratory, and 
imaging findings. Necropsy was not routinely performed. 
Survival time was defined as the interval between surgery and death. The postoperative (short-
term) period was defined as the 14 days following surgery. The long-term period started from 
this point, inclusively, forward. 
 
5. Statistical analysis 
Data was analysed using Microsoft® Excel for Mac 2016 (version 16.14.1). General descriptive 
statistics was used for both quantitative and qualitative variables. Categorical variables were 
presented as proportions or percentages. Numerical variables were expressed using mean, 
median, and range (minimum to maximum value). 
Survival analysis was achieved using R© for Mac OS X (version 3.5.0) – a free software 
environment for statistical computing and graphics, available at http://www.r-project.org. An 
overall median survival time was determined by use of the Kaplan-Meier life-table analysis. 
Dogs were censored if they were still alive at the end of the study period or if they have died 






During the 10-year study period, 16 dogs were identified that met the inclusion criteria. Nine 
were females (56.3%), 2 intact (12.5%) and 7 neutered (43.8%); and 7 were males (43.8%), 5 
intact (31.3%) and 2 neutered (12.5%). The mean age at time of surgery was 9.8 years (range 
0.8-15 years) and the mean body weight was 25.1 kg (range 7.6-46.6 kg). Breeds included were 
2 Golden Retrievers (12.5%), 2 Labrador Retrievers (12.5%), 2 Scottish Terriers (12.5%), and 
1 each (6.3%) of the following: Boxer, Brittany Spaniel, German Shepherd, Rhodesian 
Ridgeback, Tibetan Mastiff. The remaining 5 dogs were mixed breeds (31.3%). 
 
2. Preoperative evaluation 
2.1 Relevant history 
Twelve dogs (75%) had history of concomitant diseases or other neoplasms: degenerative joint 
disease (n=4), atopy (n=2), intervertebral disk disease (n=1), urolithiasis (n=1), epilepsy (n=1), 
mast cell tumour (n=2), anal gland adenoma (n=1), anal gland carcinoma (n=1), benign mixed 
mammary tumour (n=1), mammary carcinoma (n=2), and lingual plasma cell tumour (n=1). 
 
2.2 Clinical presentation 
Adrenal lesions presented as incidentalomas in 4 dogs (25%) through the use of US (n=3) or 
CT (n=1) in the control of metastases from other neoplasms (n=2), as a part of pre-anaesthetic 
geriatric procedures (n=1), or while investigating clinical signs non-related to the adrenal 
abnormality (n=1). 
Three dogs (19%) had ruptured adrenal tumours and presented with acute clinical signs, 
including collapse (n=2), lethargy (n=3), vomiting (n=3), anorexia (n=2), tachypnoea (n=1), 
tachycardia (n=1), ascites on abdominal palpation (n=3). Abdominocentesis confirmed the 
diagnosis of haemoabdomen in all 3 animals.  
In the remaining 9 dogs (56%) the most commonly observed clinical sign was PU/PD (n=6). 
Other registered clinical manifestations included: dermatological changes (n=2), abdominal 
enlargement (n=1), recurrent urinary tract infections (n=1), persistent haematuria (n=1), 
hypertension (n=1), panting (n=1), signs of anxiety (n=1), anorexia (n=2), lethargy (n=1), 
nonspecific cervical pain (n=1), palpation of a firm mass in the cranial mid-abdomen associated 




2.3 Functional testing 
Only dogs undergoing elective (n=13) adrenalectomy had functional tests performed. 
Assessment of adrenocortical functionality was performed in 9 of those (69%) and included 
ACTHST and LDDST (n=4), ACTHST only (n=2), LDDST only (n=2), or UCCR only (n=1). 
Evaluation of adrenal medullary neuroendocrine activity was performed in 4 of those (31%) 
and included measurement of urinary catecholamines and metanephrines (n=2), or 
measurement of plasma free (n=1) or total (n=1) metanephrines. 
Results of dogs that had both an ACTHST and a LDDST performed (n=4) were within reference 
limits in two dogs, inconsistent in another (ACTHST within reference limits and LDDST 
supportive of PDH), and consistent with HAC and PDH in a fourth dog; for this latter patient, 
results of plasma free metanephrines were not supportive of a productive phaeochromocytoma. 
In regard of the two dogs that only had an ACTHST performed, results were consistent with 
HAC, and in one of them, the urinary catecholamines and metanephrines assay was also 
supportive of a productive phaeochromocytoma. The two patients that only had a LDDST done, 
results were within reference limits. Lastly, one dog had UCCR results within reference limits, 
thus ruling out HAC; and plasma total metanephrines values were not supportive of a 
productive phaeochromocytoma. 
Two of the 4 dogs with adrenal incidentalomas were submitted to functional testing. In both 
cases, tests were consistent with non-productive lesions: both ACTHST and LDDST within 
reference limits in one; UCCR within reference ranges and plasma total metanephrines values 
not supportive of a phaeochromocytoma in another. 
 
2.4 Imaging assessment 
All dogs undergoing elective (n=13) adrenalectomy had their adrenal lesions preoperatively 
identified and assessed through US (n=7), CT (n=1), or US followed by CT (n=5). 
The presence of ‘true’ thrombus in CVC (n=1) was missed by US, but not by CT post-contrast 
administration scans. In the remaining 7 cases evaluated through US, the inexistence of actual 
intravascular invasion compared to extrinsic compression causing luminal narrowing was 
correctly recognised. Unfortunately, the 2 dogs in this study with CVC tumour thrombus did 
not undergo comprehensive imaging examinations because for all the cases undergoing 
emergency (n=3) adrenalectomy, imaging methods were purely used to assist the diagnosis of 
abdominal effusion – namely, US (n=2) and radiography (n=1). 
Verification of abdominal metastases was systematically performed along with evaluation of 
adrenal masses in the 13 dogs undergoing elective procedures. Intrathoracic distant spread was 
evaluated in 12 of 16 dogs either by using radiography (n=10) or CT (n=2). No evidence of 
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abdominal or pulmonary metastases was found. Yet, other major abnormalities were detected 
and included a 10-cm hepatic mass (US-FNA yielded the differentials of nodular hyperplasia 
or hepatoma), a 2.5-cm splenic mass alongside with irregular aspect of the spleen head, an      
~8-cm splenic mass in the body of the organ, both a 1.5-cm bladder calculi and a 1.65-cm renal 
pelvic calculi, a ‘true’ thrombus in the CVC, and dilatation of renal pelvis and respective ureter 
on its proximal third due to extrinsic involvement and compression by the tumoural mass (US-
FNA yielded a diagnosis of malignant neoplasia, without cytological differentiation). 
 
3. Surgical procedures and findings 
Thirteen dogs underwent elective unilateral adrenalectomy and 3 required an emergency 
adrenalectomy to stop potentially fatal blood depletion from ruptured adrenal masses. Affected 
adrenals were right-side in 12 dogs (75%) and left-sided in 4 (25%). The aspect of the masses 
varied from well encapsulated, to very friable and haemorrhagic. They also varied in size 
(Table 6) and presented different degrees of local invasiveness (addressed in detail in the 
following section). Tumour invasion of the CVC was detected intraoperatively in two dogs. 
Concurrent surgical procedures were performed in 12 dogs (75%) and included: CVC 
venotomy to remove a “true” thrombus (n=1), repair of a caval iatrogenic rupture while 
dissecting (n=1), partial resection and reconstruction of the aorta wall (1) due to an area of 
greater tumour adhesion to the vessel wall,  ipsilateral nephrectomy (n=3) when a large 
adherence between the tumour and the kidney and/or invasion of the respective vasculature was 
noted, liver biopsy (n=6), liver lobectomy (n=1) to remove a 10-cm hepatic mass, splenectomy 
(n=2) due to the presence of multiple abnormalities in one case and a single ~8-cm nodular 
lesion in the body of the spleen in another, and a salivary mucocoele excision (n=1). 
Anaesthetic and surgical times were available for 8 dogs and ranged from 110 to 300 min (mean 
217.5 min, median 232.5 min) and 60 to 215 (mean 161.25 min, median 187.5 min), 
respectively. 
 
4. Histopathological evaluation 
The adrenal specimens were submitted to histopathological examination in 13 dogs (81%). Of 
these, 8 (62%) were diagnose with adrenocortical abnormalities including carcinoma (n=4), 
adenoma (n=2), myelolipoma with nodular cortical hyperplasia (n=1), and extensive 
haemorrhage within the gland displacing the cortex and medulla without neoplastic evidence 
(n=1). The remaining 5 animals (38%) had medullary neoplasms identified, including 
phaeochromocytoma (n=4) and neuroblastoma (n=1). The 3 dogs (19%) without 
histopathological diagnosis were presented as emergencies and were euthanised during surgery. 
The owners declined necropsy. 
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The dog with a caval ‘true’ thrombus had an adrenocortical adenoma. Also, the largest tumour 
(maximum diameter of ~12 cm), which caused ipsilateral ureter extrinsic compression and aorta 
wall invasion, was diagnose as a neuroblastoma. The 4 dogs with adrenal incidentalomas were 
diagnosed with adrenocortical adenoma (n=1), extensive haemorrhage within the gland (n=1), 
and phaeochromocytoma (n=2). 
Other histopathological diagnoses included glycogen-like vacuolar hepatopathy (n=5) 
consistent with hyperadrenocorticism, chronic hepatitis (n=1), hepatocellular carcinoma (n=1), 
benign nodular lymphoid hyperplasia and extramedullary haematopoiesis (n=1), voluminous 
splenic haematoma (n=1), hydroureteronephrosis (n=1) caused by extrinsic compression of the 
ureter by the tumour, neoplastic invasion of the renal pelvis and extrinsic compression of the 
kidney by the tumour (n=1), neoplastic invasion of the peri-neural and -adipose tissue (n=1). 
Adrenal gland abnormalities were locally invasive in 6 dogs (38%), including 1 carcinoma, 1 
phaeochromocytoma, 1 neuroblastoma, and 3 without histopathological diagnosis. The tissues 
invaded were the CVC with a tumour thrombus (n=2), aorta wall (n=1), ipsilateral renal pelvis 
(n=1), renal vasculature (n=3), adrenal peri-neural and -adipose tissue (n=2), and muscle wall 
(n=1). 
Metastases were not identified in any of the dogs at time of surgery (0%). Yet, a necropsy 
performed in the only dog that died in the postoperative period (4 days after surgery) revealed 
presence of metastasis in the right cervical lymph node originating from a phaeochromocytoma. 
Therefore, it is arguable that distant spread could have already been present at time of surgery, 
altering this rate to 6%. In the long-term, metastases were diagnosed in an additional dog during 
necropsy and sites included the precordial area, mediastinal lymphatic centre area, and liver – 
the primary tumour was a neuroblastoma. 
 
5. Outcome 
Intraoperative complications were registered in 13 dogs. Twelve (92%) had intraoperative 
complications including an iatrogenic tear and subsequent repair of the CVC (n=1), prolonged 
CVC occlusion for approximately 8 min (n=1), minor (n=4) and major (n=5) haemorrhage, 
hypotension (n=5), tachycardia (n=6), and cardiac arrest (n=1). Postoperative complications 
developed in 67% of dogs who survived surgery (8/12) and included acute renal insufficiency 
(n=1), hypoadrenocorticism (n=1), pancreatitis (n=4), hypertension (n=1), cardiac arrhythmias 
(n=1), dyspnoea (n=1), DIC (n=1), diarrhoea (n=1), anorexia (n=1), wound breakdown (n=1). 
Twelve (75%) dogs survived surgery. Causes of intraoperative death included hypovolaemic 
shock following an iatrogenic tear of the CVC (n=1), and perceived lack of complete 
resectability (n=3) attributed to a combination of complicating factors – the mass’s friable 
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nature (n=2), presence of major haemorrhage (n=3), extensive degree of local invasiveness into 
the surrounding tissues in general (n=1) or into the CVC (n=2), and suspected metastatic spread 
to the spleen (n=1). The owners of the 3 latter patients (with perceived lack of complete 
resectability) were contacted at that point, and they elected euthanasia and declined necropsy 
or histopathological evaluation. During the postoperative period, 1 additional dog was 
euthanised following the development of a series of complications – hypertension, cardiac 
arrhythmias, dyspnoea, and DIC. Necropsy revealed haemothorax and -abdomen, pulmonary 
congestion, extensive subcutaneous haemorrhages, diffuse tubular necrosis and glomerular and 
interstitial fibrosis, hepatic necrosis with calcification, pyogranulomatous inflammation of the 
peripancreatic adipose tissue, and metastasis from the original adrenal phaeochromocytoma to 
the right cervical lymph node. Median hospitalisation times for those who survive surgery were 
4 days (mean 3.8 days, range 2 to 5 days). 
Overall, 11 (69%) dogs survived the immediate postoperative period, with a median follow-up 
period of 415 days (range 14-1173 days). One dog was lost to follow-up at 14 days, 7 more 
dogs died in the long-term, and 3 were known to be still alive at the end of the study. 
In total, of the 12 dogs who were known to have died (intra- and postoperatively, and during 
the long-term period), 8 (67%) were considered to have died of adrenal tumour-related (TR) 
causes and 4 (33%) of non-adrenal tumour-related (NTR) causes (Table 6). An overall median 
survival time of 419 days was obtained through Kaplan-Meier life table-analysis (Graphic 1).  
 








Status Cause of death 
1 Unknown 50 mm 0 Dead TR Tumour rupture & AAH (E) 
2 Unknown 50 mm 0 Dead TR Tumour rupture & AAH (E) 
3 Unknown 40 mm 0 Dead TR Tumour rupture & AAH (E) 
4 Myelolipoma 50 mm 0 Dead TR Hypovolaemic shock 
5i Phaeochromocytoma 35 mm 4 Dead TR Postoperative complications (E) 
6 Phaeochromocytoma 40 mm 14 Alive  NA    Lost to follow-up 
7 Neuroblastoma 121 mm 43 Dead TR Metastatic disease (E) 
8i Phaeochromocytoma 25 mm 53 Alive  NA     
9 Phaeochromocytoma 33 mm 247 Alive  NA     
10i Haemorrhage 35 mm 382 Dead NTR Congestive heart failure (E) 
11 Carcinoma 25 mm 415 Dead TR Chronic liver disease (E) 
12 Carcinoma 35 mm 419 Dead TR Chronic pancreatitis, diabetes (E) 
13i Adenoma 52 mm 521 Dead NTR Recurrent uterine infection (E) 
14 Carcinoma 20 mm 770 Alive  NA     
15 Carcinoma 45 mm 972 Dead NTR Severely compromised mobility (E) 
16 Adenoma 28 mm 1173 Dead NTR Hepatocellular carcinoma (E) 
 
Caption: AAH= acute tumour haemorrhage; E=euthanasia; i=incidentaloma; NA=non-applicable; TR=adrenal 
tumour-related; NTR=non-adrenal tumour related. *Size of tumour is characterised as the maximum diameter 
observed due to unavailability of standardised measurements or use of the same techniques; hence, the dimensions 
here presented were based on mixture of US, CT, or macroscopic measurements. 
 
 56 
In the long-term, local recurrence was not identified in any of the dogs (0%). On the other hand, 
metastases to the precordial area, mediastinal lymphatic centre area, and liver were diagnosed 
in 9% of long-term survivors (1/11). Overall metastatic rate of this study was 13% (2/16). 
 
Graphic 1. Kaplan-Meier life table analysis for overall median survival time of 419 days in 16 














Resolution of clinical signs was assessed in dogs who survived the postoperative period, with 
exclusion of those with adrenal incidentalomas because these patients had clinical signs non-
related to the adrenal abnormality or no clinical signs at all. Hence, 6 of 8 dogs (75%) had 
resolution of clinical signs. However, in 2 patients (25%) new clinical signs were registered 
which resulted directly from the adrenal disease (both had adrenocortical carcinomas removed) 
and/or the undertaken procedure itself: long-term chronic liver disease in one; and chronic 
pancreatitis and subsequent diabetes in another. Both dogs were supportively managed 
accordingly until a point where their condition had deteriorated considerably, and euthanasia 
was elected. With regard to the first dog mentioned, the possibility of metastatic disease as the 
cause or contributing factor of the chronic hepatic compromise was not totally discarded, in 
consideration of the US aspect of the liver and detection of adrenal peri-neural and -adipose 
invasion at time of adrenalectomy. Furthermore, because of this latter argument, the dog was 
submitted to one session of chemotherapy with carboplatin postoperatively, to which the patient 
reacted poorly and, consequently, chemotherapy was no longer pursued. Therefore, it is also 
possible that this treatment may have contributed to the aggravation of the liver damage. 
Recurrence of clinical signs related to the adrenal disease occurred in 1 case (1/8), at 43 days 






























diagnosed through necropsy following euthanasia. The dog had similar clinical signs to initial 
presentation and more, including prostration, anorexia, asthenia, general weakness associated 
to nonspecific pain, faecal incontinence, refusal to seat, an intense pain on abdominal palpation. 
A chemotherapy protocol after surgical removal of the primary tumour had been offered and 
declined at that time. 
In regard of the dogs with adrenal incidentalomas (n=4), whereas two had good long-term 
outcomes (one survived for 382 days and another for 521 days, and both died of NTR causes), 
one was still alive and well at 53 days postoperatively, and a fourth dog died 4 days after surgery 
following the occurrence of a series of complications already outlined. It is possible that these 
were consequential to a productive phaeochromocytoma, although no signs of activity were 
noted beforehand; thus, surgical manipulation might have triggered those events by causing a 





Age, gender, weight, and breed of the population of this study were consistent with previous 
reports of similar spectrum (Anderson et al., 2001; Barrera et al., 2013; Herrera et al., 2008; 
Kyles et al., 2003; Lang et al., 2011; Massari et al., 2011; Schwartz et al., 2008; van Sluijs et 
al., 1995). The only major difference detected involved the age range, specifically the minimum 
age registered, which can easily be explained by the fact that one animal had a neuroblastoma, 
an adrenal tumour which typically occurs in young animals rather than in middle-aged to older 
individuals like adrenocortical tumours and phaeochromocytomas (Rosol & Gröne, 2016; 
Reusch, 2015). If that dog was to be excluded, age would vary between 7.9 to 15 years old 
(mean 10.4 years); thus, in accordance with other case series. Weight-wise it was interesting to 
see that 81% of dogs weighed more than 15 kg. Massari et al. (2011) had reported that 40.4% 
of their canine population with adrenal tumours weighted more than 15 kg, compared to 36.5% 
weighing 15 kg or less. Moreover, Reusch & Feldman (1991) had also noted that 46% of their 
dogs with ATs weighed more than 20 kg in comparison to 77% of dogs with PDH who weighted 
< 20 kg. Although these results might suggest a tendency for adrenal tumours to occur with 
increased frequency in larger breed dogs, it is also possible that these findings were influenced 
by elevated body condition scores, which were not determined in any case. 
Predictably, considering the advanced age of these patients (Reusch, 2015), a high proportion 
of dogs (75%) had history of concurrent diseases or other neoplasms. Coexistence of non-
adrenal diseases may interfere with results of functional tests (Cameron et al., 2010; Gostelow 
et al., 2013; Salesov et al., 2015) and, more importantly, may influence prognosis, especially 
on long-term. For instance, upon removal of cortisol-producing ATs, clinical signs of atopy or 
degenerative joint disease may be unmasked as cortisol concentrations decrease (Behrend, 
2015). Yet, here, none of the dogs had pre-diagnosed conditions associated with the necessary 
severity to cause that negative impact on outcome, i.e., they did not preclude adrenalectomy. 
In regard of clinical presentation, there was a considerably high proportion (3/16) of dogs 
presented as surgical emergencies due to tumour rupture and AAH in comparison to others 
studies of similar design – 8/60 (Lang et al., 2011) and 4/86 (Barrera et al., 2013). Additionally, 
and even though traumatic and non-traumatic rupture of adrenal tumours resulting in 
intraabdominal or retroperitoneal bleeding has been considered a rather rare event, reported in 
a total of 20 cases (Barrera et al., 2013; Evans et al., 1991; Lang et al., 2011; Santamarina et 
al., 2003; Vandenbergh et al., 1992; Whittemore et al., 2001; Williams & Hackner, 2001). 
Hence, this study might suggest that this scenario is more common than previously thought. 
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Yet, it should be beared in mind that these results might also be coincidental. The described 
clinical signs were identical to previous reports. 
On the other hand, for patients undergoing elective adrenalectomies, clinical signs that lead to 
the investigations were neither numerous and, sometimes, nor exuberant, with PU/PD being the 
most common complaint. This was probably a result of heightened awareness of HAC, which 
makes dogs being examined at much earlier stages of disease development and, in turn, clinical 
manifestations will be more subtle and less prevalent in individual dogs; likewise, reference 
ranges of functional testing might need to be readjusted (Behrend et al., 2013). 
With regard to phaeochromocytoma-orientated functional assays, in here, 4 dogs had assays 
performed. Results of urinary catecholamines and metanephrines were supportive of productive 
phaeochromocytomas in 2 dogs. Yet, both animals also had ACTHST suggestive of HAC, and 
histopathological examination yield a diagnose of adrenocortical carcinoma. This situation 
exemplifies the previously pointed out difficulty in differentiating animals with HAC and 
phaeochromocytoma through these tests, considering that results of dogs with HAC can overlap 
with those with phaeochromocytomas (Quante et al., 2010). For the other 2 patients, plasma 
free or total metanephrines were measured, and results were deemed non-supportive of 
productive phaeochromocytomas – one had an adrenocortical carcinoma and the other a 
phaeochromocytoma diagnosed through histopathological evaluation. For this latter dog, 
although it is possible that the medullary tumour was non-functional since it was incidentally 
discovered with no clinical signs associated, it is also feasible that because of its small 
dimensions (25 mm in maximum diameter) these results were below the sensitivity of the test 
(Reusch, 2015). Besides, even if the phaeochromocytoma was indeed non-functional at that 
stage, there was no way to tell if it would or not become functionally active with time. 
In this study, 25% (4/16) of dogs had adrenal incidentalomas, discovered through imaging 
methods such as US and CT, which is a considerably high proportion to take into account, also 
in comparison with other studies: 3/39 (Kyles et al., 2003), 2/60 (Lang et al., 2011). 
Nevertheless, this event is not surprising and has been predicted by other authors (Baum et al., 
2016; Cook et al., 2014; Myers, 1997). Previously, it has been argued that there might be a  
~14-30% chance of an adrenal incidentaloma being malignant and they might become 
functionally active with time (Cook et al., 2014). Moreover, for any mass measuring ≥ 20 mm 
in maximum diameter, the likelihood of malignancy (Cook et al., 2014; Labelle et al., 2004) 
and growth potential (Arenas et al., 2013) might also be high. In here, half of the dogs with 
incidentalomas had no clinical signs and the other half had non-related manifestations. 
Moreover, whereas functional testing performed in 2 dogs confirmed the suspected inexistence 
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of productive activity, one of the dogs not tested died after development of postoperative 
complications which were suspicious of a productive phaeochromocytoma – this patient was 
also the only one of the 4 with confirmed malignancy upon discovery of distant spread at 
necropsy. Still, malignancy rate of incidentalomas could actually have been superior (2/4) if 
the other dog with a phaeochromocytoma was to be included, especially in consideration of the 
argument that phaeochromocytomas are typically reckoned to be malignant in dogs (Reusch, 
2015). Overall, 75% of patients diagnosed with adrenal incidentalomas presented an inherent 
potential to cause a problem: in respect of their proven malignancy and suspected functionality; 
high likelihood of malignancy; or large dimensions (52 mm in maximum diameter) associated 
with the prospect of an eventual rupture, even though the tumour was benign (adrenocortical 
adenoma). 
Intraoperative complications rate in this study was high (92%) and superior to the highest rate 
previously reported (83%) (Barrera et al. 2013). This proportion has ranged from 15 to 83% in 
three different studies (Barrera et al., 2013; Kyles et al., 2003; Lang et al., 2011), which is likely 
due to the use of different criteria to include or exclude a specific complication. While this 
explanation might also justify the higher rate of intraoperative complications in this study, 
surgeon’s experience should also be considered as a relevant factor since the procedure was 
undertaken by different surgeons with equally different levels of experience. 
Nevertheless, it is consensual that complications can be worrisome. In fact, in this study, one 
of these (an iatrogenic tear of the CVC) resulted in death. A situation of this nature could be 
prevented by placing Rumel tourniquets systematically, independently of existence or not of 
CVC invasion, which would be tightened if such an event was to occur. However, in practice, 
accomplishing their placement can be challenging, with risk of causing rupture as well, not to 
mention that is time-consuming which might affect outcome – Herrera et al. (2008) found that 
the longer the surgical time, the poorer the survival of dogs with phaeochromocytomas. In 
contrast, another complication of note in this study was a prolonged CVC occlusion for 
approximately 8 minutes, from which the patient had a full haemodynamic recovery. This case 
agrees with previous reports supporting the ability of canine patients to survive prolonged acute 
CVC occlusions (Halwagi et al., 2017; Horvath & Bender, 1961; Hunt et al., 1992). 
Postoperative complications have been reported to develop in 30 to 51% of dogs following 
adrenalectomy (Barrera et al., 2013; Kyles et al., 2003; Lang et al., 2011; Schwartz et al., 2008). 
Here, they occurred in 67% of patients and, similarly to the results presented by Schwartz et al. 
(2008), 38% (3/8) developed more than 1 complication. Pancreatitis was the most commonly 
diagnosed complication (4/13), observed in 25% (3/12) of right-sided procedures and 25% (1/4) 
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of left-sided. Despite the fact that right-sided adrenalectomy requires greater manipulation of 
the pancreas, pancreatitis developed in similar rates for each side intervened. Furthermore, other 
studies have helped deconstructed the preconception that pancreatitis would be exclusive of 
(Schwartz et al., 2008) or more common in dogs undergoing right-sided adrenalectomy, 
particularly by finding that side of surgery was not statistically significantly associated with the 
development of pancreatitis (Barrera et al., 2013). In the population here studied, it also 
appeared that postoperative complications occurred more frequently in dogs with ATs (5/6) 
compared to those with phaeochromocytomas (2/4). However, previous studies found no 
significant differences (Barrera et al., 2013; Kyles et al., 2003). 
Overall perioperative mortality (including all dogs that died in surgery and in the postoperative 
period) was 31%. This rate is slightly higher compared to a range varying from 12 to 26% for 
dogs with adrenal tumours in general undergoing adrenalectomy, reported in preceding case 
series (Barrera et al., 2013; Kyles et al., 2003; Lang et al., 2011; Massari et al., 2011; Schwartz 
et al., 2008). Yet, the population here presented had a higher proportion of dogs (19%) 
undergoing surgery due to tumour rupture and AAH compared to other authors, as formerly 
discussed. What is more, Lang et al. (2011) found that dogs with AAH had a significantly 
increased risk of perioperative mortality in comparison to those that underwent elective 
adrenalectomy, with a reported mortality rate of 50%. Plus, even though the 3 dogs with AAH 
in this study were euthanised intraoperatively, it is likely that they would have reached that 
outcome anyway in the postoperative period, according to Lang et al. (2011). Therefore, if only 
those undergoing elective procedures were to be considered, mortality would compare 
favourably to previous case series (15%).  
When all adrenal gland tumours are considered, overall MST reported has varied from 375 to 
953 days (Lang et al., 2011; Massari et al., 2011; Schwartz et al., 2008), and in one study 65% 
survived more than 1 year following surgery, up to 1941 days (~5 years) (Massari et al., 2011). 
Here, a comparable overall MST of 419 days was reached (Graphic 1). Moreover, at the end 
of this study, 64% of dogs who survived the postoperative period had lived for more than 1 
year, and up to 1173 days (~3 years). And also, of those who had not reached 1 year of survival, 
only 1 had died of TR causes, and of the remaining 3, one was lost to follow-up and two were 
still alive and well (Table 6). 
Adrenalectomy offers at least as good a prognosis as chronic medical management. In fact, 
even with its limitations, medical therapy with trilostane and mitotane in dogs with ADH can 
be a viable alternative to surgery, with reported MST of 353 and 102 days (Helm et al., 2011), 
respectively; and of 14.0 and 15.6 months (Arenas et al., 2014), respectively. In another study, 
 62 
regarding the course of dogs with non-cortisol-secreting tumours without adrenalectomy, MST 
was 17.8 months (552 days) (Arenas et al., 2013). Even though these MST can sometimes be 
similar or superior to surgical reports, this retrospective study inclusively, most case series have 
reported higher MST especially if dogs survive the short-term period: with adrenocortical 
adenomas, MST were 688 days (Schwartz et al., 2008); with adrenocortical carcinomas, MST 
were 778 or 992 days if they survived the postoperative period (Anderson et al., 2001), 230 
days overall (Schwartz et al., 2008), 360 days (Massari et al., 2011), and 48 months (Barrera et 
al., 2013); with adrenal tumours in general, MST were 690 days overall (Schwartz et al., 2008), 
375 or 492 days if they survived the postoperative period for elective procedures, 208 or 844 
days for emergency procedures (Lang et al., 2011), and 953 days overall (Massari et al., 2011). 
Furthermore, no successful medical treatment exists for phaeochromocytomas in detriment of 
the surgical route, and most dogs succumb to the disease and associated complications rather 
quickly (Reusch, 2015). 
Metastatic rate at surgery was questionable (0 or 6%), and in the long-term, while local 
recurrence was not identified in any of the dogs, distant spread was diagnosed in 1 of 11 dogs 
(9%) that survived long-term. Overall metastatic rate of this study was 13%. These are quite 
low rates and comparable to other studies (Anderson et al., 2001; Barrera et al., 2013; Kyles et 
al., 2003; Massari et al., 2011; Schwartz et al., 2008). Possible explanations include an 
improvement in preoperative diagnostics, leading those dogs with metastasis to non-surgical 
treatment options and, therefore, being excluded; or it may result from the real number of 
eventual metastases being underestimated, considering that necropsy was rarely pursued. If 2 
additional dogs with suspected metastatic lesions (one with suspected spleen metastasis who 
was euthanised at surgery; and another who developed chronic liver disease in the long-term 
for which US aspect of the liver and presence of invasion of adrenal peri-neural and -adipose 
tissue at time of surgery granted cause for suspicion), but without histopathological 
confirmation, were to be included, metastatic rate would be 25%. A similar conclusion was 
drawn by Barrera et al. (2013) in their case series. 
Previous investigators have evaluated prognostic factors, namely predictors for short-term 
survival, for dogs with different types of adrenal gland neoplasms undergoing adrenalectomy. 
Preoperative variables significantly associated with shorter survival times included adrenal 
gland tumour size (particularly, when the major axis length was ≥ 5cm), vein thrombosis, 
extensive invasion of the CVC (into or beyond the hepatic hilus), weakness, lethargy, increased 
blood urea nitrogen concentration, thrombocytopenia, increased partial thromboplastin time, 
increased aspartate transaminase, hypokalaemia, presence of metastases, and presence of AAH 
(Barrera et al., 2013; Lang et al., 2011; Massari et al., 2011; Schwartz et al., 2008). 
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Intraoperative variables significantly associated with shorter survival times included blood loss 
requiring transfusion, and concurrent nephrectomy (Barrera et al., 2013; Schwartz et al., 2008). 
Postoperative variables significantly associated with shorter survival times were development 
of pancreatitis, acute renal failure, DIC, hypotension, and hypoxemia (for which PTE is a 
possible cause, although it could not be confirmed due to the retrospective nature of the studies) 
(Barrera et al., 2013; Schwartz et al., 2008). 
In this study, although no statistical comparisons were feasible, these cases may serve as 
supportive examples of formerly identified prognostic factors in the referred literature. 
Nonetheless, they are representative of individual animals. 
Size-wise, 3 of 5 dogs with tumours measuring ≥ 5 cm in maximum diameter died in surgery. 
Two had acute adrenal haemorrhage –  an event that for each 1 mm increase in tumour size 
suffers a 6% increase in odds of occurrence (Lang et al., 2011). The third dog had a 50-mm 
myelolipoma, which because of its dimensions and very intimate association with the CVC, 
lead to an iatrogenic rupture of the vessel, culminating in hypovolaemic shock, cardiac arrest, 
and death. This case, along with another case of a 52-mm adrenocortical adenoma, serve as 
examples of the fact that even benign adrenal tumours may grow into considerably large 
dimensions, comparable to those of malignant masses. Therefore, large neoplasms may not only 
generate difficulties on their own by making surgical resection more challenging and risky in 
terms of causing iatrogenic injuries, but also by their augmented intrinsic potential to rupture 
and generate AAH – also a factor associated with a poorer outcome (Lang et al., 2011). 
Additionally, vein thrombosis has also been significantly associated with a tumour major axis 
length of ≥ 5 cm, and represents another characteristic which can potentially cause a negative 
impact on outcome (Massari et al., 2011). Regarding the 2 remaining dogs with tumours 
measuring ≥ 5 cm in maximum diameter, one had a neuroblastoma and died at 43 days 
postoperatively after recurrence of clinical signs and diagnosis of metastases; though Massari 
et al. (2011) found no significant association between presence of metastasis and a tumour 
major axis length of ≥ 5 cm. The other patient had an adrenocortical adenoma, survived for 521 
days, and died from NTR causes. 
Even though the cases reported here support the role of tumour size as an influencing outcome 
factor, on its own or through inherent associations with equally negative prognostic impact, it 
should be considered that size measurements in this study were unavoidable obtained through 
a mixture of methods. As a result, dimensions hereby reported might have been misjudged. For 
instance, underestimation of measurements is a well-known phenomenon associated with US 
(Behrend, 2015; Pagani et al., 2016). 
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Vein thrombosis was identified as a significant prognostic factor for decreased survival in one 
study (Massari et al., 2011). Conversely, others have found that CVC invasion did not 
significantly affect short-term morbidity or mortality, provided that the surgeon was 
familiarised with appropriate techniques (Kyles et al., 2003) and the tumour thrombus did not 
extend into or beyond the hepatic portion of the CVC (Barrera et al., 2013). In this group of 
dogs, two had CVC invasion unexpectedly discovered at surgery along with acute adrenal 
haemorrhage. In their situations, because the surgeon’s experience dictated that only partial 
resections (without thrombectomy) could be accomplished, and in consideration of the poor 
outcome associated with acute adrenal haemorrhage, euthanasia was elected. Therefore, these 
cases serve more as an example to stress how the surgeon’s experience with the surgical 
procedure and associated techniques may affect outcome as well, rather than the mere existence 
of a CVC thrombus. 
Presence of metastasis at time of surgery was possibly present in one dog (6%), confirmed 
histologically at 4 days after surgery when the animal was euthanised and submitted to 
necropsy. Another dog had suspected metastatic lesions in its spleen at time of surgery, though 
it could not be confirmed, as he was euthanised at that time – he had also a ruptured tumour, 
acute adrenal haemorrhage, and extensive local invasion into surrounding tissues. Both these 
situations exemplify how detection of metastasis at surgery can affect short-term survival. 
Likewise, presence of acute adrenal haemorrhage in this study was registered in 3 dogs, all of 
which ended up being euthanised for a combination of reasons. Although these results are 
suggestive of AAH as a negative prognostic factor for short-term survival, it should be noted 
that in the study by Lang et al. (2011) none of the dogs died intraoperatively. Still, it is likely 
that they would have reached that outcome in the postoperative period anyway, as it was 
previously argued in here. 
In regard of intraoperative complications, major haemorrhage requiring transfusion was noted 
in 5 dogs, 3 of which were cases presented with AAH and another had major haemorrhage as a 
result of iatrogenic injury of the CVC – all 4 died intraoperatively. As such, these cases are 
supportive of major haemorrhage as prognostic factor, even though for the animals with AAH 
it is questionable if there were other variables to have weighed more in the decision for 
euthanasia. Conversely, a fourth animal who had major haemorrhage due to concurrent liver 
lobectomy lived a completely different path. Not only did he survived the short-term period, 
but he also presented the longer survival time of this retrospective study, having died of NTR 
causes at 1173 days following adrenalectomy. 
 65 
Concurrent nephrectomy was identified as negative prognostic factor by Schwartz et al. (2008), 
however, later on Barrera et al. (2013) did not find nephrectomy to be a direct risk factor for 
decreased survival rate. However, MST was negatively affected because it was associated with 
development of renal failure, which in turn, was identified as a risk factor for death in the short-
term. This might explain why the 3 dogs in this study, who had concurrent nephrectomy, did 
not seem to have affected short-term survival – one was alive and well when was lost to follow-
up at 14 days after surgery; another survived for 43 days and died following development of 
metastatic disease; and a third patient was euthanised at surgery but for other reasons – since 
none developed renal failure. 
In the postoperative period, pancreatitis was diagnosed in 4 dogs. Two were still alive and well 
at 53 and 770 days, and two had died at 521 days postoperatively from NTR causes and at 419 
days from TR causes. In fact, for this latter case, the dog had a chronic form of pancreatitis, 
which eventual lead to euthanasia, and this scenario had started in the postoperative period as 
an acute form of pancreatitis. Therefore, for this case, it is possible that the development of 
pancreatitis affected its long-term survival but not its short-term. 
These results do not particularly support the factor as of short-term prognostic value. Still, the 
use of different criteria to diagnose the complications might explain it. For instance, some of 
the cases here presented were diagnosed on the basis of clinical signs and response to therapy, 
rather than obtaining confirmation with canine-specific pancreatic lipase immunoreactivity 
assay and ultrasonographic evaluation for every single case. On the other hand, Schwartz et al. 
(2008) noted that all dogs that developed pancreatitis also had acute renal failure; hence, there 
is a chance that the predominating factor was actually the acute renal failure rather than the 
pancreatitis. In here, even though one dog developed transient acute renal insufficiency in the 
postoperative period, none had renal failure. 
DIC developed in one patient in the postoperative period, together with hypertension, cardiac 
arrhythmias and dyspnoea, which due to their combined severity lead to the euthanasia of the 
animal. This example shows how DIC might contribute to or directly compromise short-term 
survival. 
Finally, Herrera et al. (2008) found that age of their dogs with phaeochromocytomas had a 
significant negative effect on survival, i.e., for every 1-year age increase, the odds of 10-day 
survival decreased by 33%. In this study, patients with phaeochromocytomas were 
approximately 7, 8, 10, and 15 years old. The two younger animals were still alive and well at 
53 and 247 days, postoperatively. In regard of the two older dogs, one (the 10-year old) was 
lost to follow up at 14 days, and the other (the 15-year old) died secondarily to a series of 
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postoperative complications; thus, representing an example which is in accordance with what 
was reported by Herrera et al. (2008). 
Overall, and most importantly, this study allows a reinforcement of the idea that if dogs survive 
the immediate perioperative period, long-term outcome is generally good with possibility of 
prolonged survival times, as local or distant tumour recurrence appears to be low, as previously 
reported (Anderson et al., 2001; Barrera et al., 2013; Barthez et al., 1997; Gilson, Withrow, & 
Orton, 1994; Kyles et al., 2003; Lang et al., 2011; Massari et al., 2011; Schwartz et al., 2008; 
van Sluijs et al., 1995). 
Limitations of this study were associated with its retrospective design, occasionally resulting in 
incomplete clinical and follow-up data, especially for dogs treated early in the study period. 
Furthermore, the reduced number of eligible cases, the variability existent in the selected group 
regarding the histological type of adrenal lesions, concurrency of other neoplastic lesions, and 
performance of surgical procedures on top of adrenalectomy, prevented unravelling more 
precise information concerning outcome of specific adrenal tumours or surgical techniques. 
Indeed, such missing data and heterogeneity of the one available, resulted in an even smaller 
effective sample size, precluding further statistical analysis with reliability beyond a general 
descriptive exploration and a straightforward survival analysis through a Kaplan-Meier 
estimate allowing characterization of death in the population over time. Besides, a 
comprehensive survival analysis was also compromised by animals lost to follow-up, animals 
recently intervened thus limiting information regarding their long-term outcome, occasional 
bias in discriminating cause of death between pre-established groups (necropsy was seldom 
performed), and a high proportion of cases succumbing of NTR causes. 
Additionally, and notwithstanding the discussed evidence, it is recognised that outcome might 
have been potentially biased by variation in clinicians' recommendations and owners' decisions 
(for instance, regarding a patient’s fittingness for undertake surgery), and surgical technique. 
Indeed, the technical difficulties that adrenalectomy imposes and their degree of influence on 
outcome cannot be undervalued, and the fact that, in this study, different surgeons with equally 
different degrees of experience undertook the procedure might have impacted outcome as well. 
Moreover, follow-up examinations were also completed by different veterinarians which might 
have affected the diagnosis of some complications since confirmation testing was not always 
performed for every case. Also, outcome could not be always objectively evaluated, sometimes 
having to rely on general satisfaction and feedback from owners. 





Overall, this study emphasizes the conception that if dogs survive the immediate perioperative 
period, long-term outcome is generally good with possibility of prolonged survival times, as 
local or distant tumour recurrence appears to be low, just like has been previously reported 
(Anderson et al., 2001; Barrera et al., 2013; Barthez et al., 1997; Gilson, Withrow, & Orton, 
1994; Kyles et al., 2003; Lang et al., 2011; Massari et al., 2011; Schwartz et al., 2008; van 
Sluijs et al., 1995). 
In this study, 25% of dogs had adrenal incidentalomas discovered through imaging methods. 
In spite of this rate representing a considerably high proportion to reflect on, it does not 
exemplify an absolute unexpected finding. What is more, 75% of these had potential to be 
problematic in consideration of their proven malignancy and suspected functionality, high 
likelihood of malignancy, or large dimensions with potential to rupture (even though the tumour 
was benign). In reality, there is no way to tell how an incidentaloma will evolve over time, and 
surgical intervention sooner rather than later might be the safest way to guaranty a good 
prognosis. Still, it is recognised that not all dogs will be fitting candidates to adrenalectomy in 
consideration of their advance age and inherent concurrent frailties. 
It should be also outlined that a substantial proportion of dogs (19%) in this case series were 
presented as medical and surgical emergencies due to a ruptured tumour and acute adrenal 
haemorrhage, which might indicate that these scenarios are more common than previously 
thought. Furthermore, surgeon’s awareness of this situations might be critical as their 
experience and knowledge in how to surgical manage them can have an important effect on 
outcome, as also suggested by this study.  
In sum, and in spite of its limitations, this retrospective investigation serves as an example of 
previously argued outcome predictors to consider when approaching these cases: age of patients 
with phaeochromocytomas, size of tumour, surgeon’s experience in dealing with CVC 
invasion, presence of metastasis at surgery, acute adrenal haemorrhage, major intraoperative 
haemorrhage, and postoperative DIC. It also promotes awareness of adrenal incidentalomas 
and emergency clinical presentations. In addition, one can infer that having the experience and 
knowledge to surgical handle the adrenal glands might be a vital competence even for surgeons 
working at majorly first-opinion institutions which also offer a first-line of surgical options and 
referral work, in consideration of the three clinical cases here presented as candidates of 
emergency exploratory laparotomies due to an haemoabdomen of unknown origin, and only 
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